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Poxviruses are an important family of viruses with members capable of infecting 
humans including variola virus, the causative agent of smallpox. Homologs of the 
variola virus B22 protein are found in almost all chordopoxviruses and have 
estimated masses of greater than 200 kDa, making them the largest known poxvirus 
proteins, and leading to our initial interest in the role of this protein family. Most 
homologs are found in the variable region of the poxviral genome where less 
conserved host-interaction proteins are found, however, B22 homologs are 
remarkably well conserved, missing only from the parapox subfamily and vaccinia 
virus, and sometimes even found in multiples (crocodilepox, canarypox) despite their 
large size.  We showed that the cowpox homolog, CPXV219, was expressed early 
during infection and cleaved into fragments that remained associated. CPXV219 was 
observed in the secretory pathway and at the plasma membrane with the majority of 
 
 
the protein extracellular. However, mutants that did not express CPXV219 replicated 
normally in cell culture and retained virulence in a mouse respiratory infection model. 
Next, we investigated the importance of the ectromelia virus homolog C15 in the 
natural infection model, mousepox. In the absence of C15 following footpad infection 
of BALB/c mice, there was less mortality and at high doses all mice survived, 
whereas none survived infection with wildtype virus. Similar virus loads were present 
at the site of infection with mutant or control virus whereas there was less virus in 
popliteal and inguinal lymph nodes, spleen and liver, key organs in mousepox 
disease, indicating decreased virus spread and replication in the absence of C15. 
Decreased spread was not the result of an intrinsic viral function of C15 as the 
survival of infected mice was dependent on host CD4+ and CD8+ T cells during 
infection. These results highlight the importance of choosing an appropriate animal 
model. The influence of B22 homologs displays a species-specificity as observed in 
the natural virus-host model of ectromelia virus, which provides an excellent model 
for the study of such host-defense molecules during poxvirus infection. Future work 
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Smallpox is one of the most devastating diseases in human history. Variola virus is 
the causative agent of smallpox and a member of the Orthopoxviridae (OPXV) which 
contains multiple double stranded DNA viruses capable of infecting humans. The 
smallpox epidemic was finally brought under control by the development of the first 
vaccine, a live attenuated vaccinia virus. Introduced by Edward Jenner in 1796, 
material from the lesion of a dairymaid, presumably cowpox, was demonstrated to 
protect against smallpox. A worldwide vaccination campaign was launched in 1966 
using the presumed viral descendant, vaccinia virus (VACV), by the World Health 
Organization and eventually led to the eradication of smallpox disease in the natural 
world by 1980. Rare, but serious complication led to the cessation of regular 
vaccination for the general populous and currently only military and research 
personnel are regularly vaccinated (1, 2).  
There is a need for continued research and a better understanding of 
poxviruses in general as there are ongoing OPXV epidemics in humans and animals 
around the world (3), as well as a potential for new emerging zoonotic poxviruses 
capable of infecting humans, and the potential use of smallpox for bioterrorism (2). 
VACV, the smallpox vaccine, has been the best characterized poxvirus but repeated 




The primary goal of this dissertation was to characterize a large family of 
proteins present in almost all chordopoxviruses, the B22 family of proteins. 
Homologs of the variola virus B22 protein represent the largest poxviral genes, 
typically greater than 200 kDa in size, and are found in all chordopoxviridae, with the 
exception of the parapox genus and VACV. This conservation is despite being found 
most commonly in the variable region of the genome among genes that encode 
primarily host-interaction proteins. Along with its absence in the attenuated VACV, 
the lack of prior research, strong conservation and large size of these proteins made 
B22 homologs an interesting subject to study.  
Cowpox virus (CPXV), another member of the OPXV and possible parental 
virus of the smallpox vaccine VACV, contains all of the open reading frames 
represented within the OPXV (5). As such, CPXV presents an opportunity to study 
genes absent from VACV and in the presence of all other OPXV proteins. The B22 
family member in CPXV is open reading frame 219 (CPXV219) and was found to be 
expressed early during infection and trafficks to the surface of infected cells. The 
majority of the protein is extracellular and thus poised to interact with the host 
immune response, however, absence of CPXV219 did not affect disease pathogenesis 
in laboratory mice as discussed in Chapter 3. 
Ectromelia virus (ECTV) the causative agent of mousepox, is a unique 
member of the OPXV with a known natural host of laboratory mouse strains such as 
BALB/c. In Chapter 4, the use of this known virus/host paired model is used to better 
examine the role of the B22 family member, C15, during disease. The footpad 




examination of the virus spread in the presence or absence of C15 and the host 
response to infection. Absence of C15 resulted in complete host survival at high viral 
doses dependent on the presence of CD4+ or CD8+ T cells. Virus replication at the 
site of infection was not affected by the absence of C15, but viral dissemination and 
replication in key organs such as lymph nodes, liver and spleen was reduced. 
Altogether, the findings of this work provide a picture of how B22 homologs 
influence disease outcome during poxvirus infection and highlight the importance of 
carefully choosing a disease model. Our work with ECTV suggests B22 homologs 
may influence the immune response in a T cell-dependent and species-specific 
manner. Future work is needed to better understand how the B22 family of proteins 
interact with and influence the host immune response to poxviral infection and how 
this may vary in efficacy or species-specificity between viruses and hosts. 
 
Chapter 3 includes work that has been previously published in the journal 
Virology. Laboratory experiments were performed by me, and experimental designs 
and publication was achieved through collaborative efforts with my supervisor, 
Bernard Moss. Adapted from: Reynolds, S. E. and Moss, B. Characterization of a 
large, proteolytically processed cowpox virus membrane glycoprotein conserved in 





Chapter 2: Literature Review 
 
 
2.1 The Poxviridae 
2.1.1 Classification 
The Poxviridae are a family of large, enveloped, double-stranded DNA (dsDNA) 
viruses that replicate in the cytoplasm of host cells. These brick-shaped viruses 
contain enzymes that synthesize mRNA and a dsDNA genome of 134-300 kilobase 
pairs (kbp) organized with a hairpin loop at both ends. Subfamilies are divided based 
on host range. The subfamily Chordopoxvirinae infect vertebrate hosts, and the 
Entomopoxvirinae infect insect hosts. Despite distinct host ranges, DNA sequences 
and bioinformatics confirm the genetic relationship between these two subfamilies (6, 
7), and also suggest that the Poxviridae may be distantly related to Asfaviridae, 
Iridoviridae, Phycodnaviridae (8) and Mimiviruses (9), other large DNA viruses that 
replicate in the cytoplasm. Together these viruses have been named the Nucleo-
Cytoplasmic Large DNA Viruses (NCLDV) and likely share a common ancestor (8). 
 The Chordopoxvirinae subfamily contains 10 genera (International 
Committee on Taxonomy of Viruses 2015 (10)): Avipoxvirus, Caporipoxvirus, 
Cervidpoxvirus, Crocodylidpoxvirus, Leporipoxvirus, Molluscipoxvirus, 
Orthopoxvirus (OPXV), Parapoxvirus, Suipoxvirus, and Yatapoxvirus (Fig 2.1) along 






Figure 2.1 Phylogenetic relationship between Poxviruses 
Amino acid alignment of 20 conserved genes is used in determination of phylogenetic 
relationships by Hendrick, R.C. et al. (4). This prediction represents one possible tree, 
however, other comparative methods have generated slightly different evolutionary 
relationships. Predicted tree is represented with branches labeled by genus name and 
the prototypic species for each genus in parentheses. Unclassified viruses have not yet 
been assigned to a taxon. Figure reprinted with permission under the shared creative 





poxviruses continue to be identified on a regular basis (12-14) and expand the 
diversity of this family. Classification of viral species within each genera is based 
upon criteria such as host range, genetic similarity, particle morphology and antigenic 
relatedness (10, 15). Among these only OPXV and Molluscipoxvirus contain obligate 
human pathogens, variola virus (VARV) and molluscum contagiosum virus (MOCV), 
respectively. Additional viruses from OPXV, Parapoxvirus and Yatapoxvirus genera 






Table 2.1 Non-Orthopoxviruses that can infect humans 
Outside of the OPXV genus, only three genera are known to be capable of infecting 
humans. Of these, only MOCV is an obligate human pathogen. Clinical signs of 
disease in humans and host species for each virus are listed in columns three and four, 





The OPXV genus includes multiple viruses capable of infecting humans and has thus 
been the most extensively studied. The most famous member is the variola virus 
(VARV), causative agent of smallpox, perhaps the most devastating disease in human 
history. There is no way to accurately estimate the toll of smallpox throughout human 
history but it is clearly an ancient and devastating disease. Indeed, the mummified 
remains of Ramses V (died 1156 BC) bear the marks of the disease (17), VARV 
contaminated blankets were used as the first examples of biological warfare during 
the French-Indian war (1754-1767) (18), and in 1777 George Washington had 
ordered the American army variolated (19).  
The process of variolation describes the use of material from a fresh smallpox 
pustule to intentionally inoculate a patient and was practiced in Africa, India and 
China long before the 18th century. The goal is to induce a mild, localized form of the 
disease that results in life-long protection from reinfection, however, it does pose a 
risk for developing the full smallpox disease course and possibly death.  
In 1797, Edward Jenner published his findings that a similar inoculation using 
material from the pustule of dairy maids resulted in the same level of protection, but 
without the risks of using VARV. The material used was likely a cowpox virus 
(CPXV) and as the Latin word for cow is vacca, thus vaccinia virus (VACV) and the 
term vaccine (1). Over the next two centuries this material was passaged through 
many people, and later cows, resulting in the phylogenetically distinct VACV species 
used during the final eradication campaign of smallpox. As VARV is an obligate 




Organization (WHO) was able to use localized VACV vaccination campaigns to halt 
the person-to-person transmission of VARV. Efforts were aided by the life-long 
protection of vaccination or surviving smallpox, and the scarring that results from 
pustules marks individuals who are protected. Ultimately, in 1977 WHO achieved the 
first ever eradication of a disease from the natural world (2).  
Although vaccination against smallpox has ceased, interest in VACV as a 
vector for new vaccines or therapeutics for a variety of infectious agents and cancer 
has emerged (20, 21). However, lack of smallpox vaccination has left behind a more 
susceptible population of human hosts (2, 22) and a variety of other OPXV have the 
potential to infect non-vaccinated humans (Table 2.2). Zoonotic transmissions have 
appeared with monkeypox virus (MPXV) in Africa and, for the first time, in the 
United States in 2003. Concerns about bioterrorism have emerged due to the 
similarity in appearance of this disease with smallpox, as well as a demonstrated 
potential for person-to-person transmission and up to 10% lethality in humans (23, 
24).  
CPXV is endemic in Europe and infects humans via zoonosis with infections 
among both animals and people on the rise (25). Infections with CPXV can be serious 
though rarely disseminate or are fatal (3, 26). The VACV has also begun circulating 
among cattle in Brazil, raising agricultural concerns (27). Thus, there remains an 
interest in the study of poxvirus therapeutics and vaccines. 





Table 2.2 Orthopoxvirus Host Ranges 
Orthopoxviruses are listed along with species who have been reportedly infected, a 
generalized overview of the host species range, and the natural host, if known. Table 




reading frames found in OPXV species, while each of the other OPXV species 
contains some subset of those genes. CPXV has a very broad host range although the 
natural reservoir, suspected to be voles, is poorly documented or understood (28). The 
primary vector for transmission to people are domestic cats and rodents, although less 
conventional transmissions such as to monkeys and elephants have been reported (3). 
 Other members of the OPXV include camelpox virus, ectromelia virus 
(ECTV), racoonpox virus, skunkpox virus, taterapox virus and volepox virus. 
Mousepox, caused by ECTV, will be discussed extensively later in this chapter. 
Camelpox disease is camel-specific, but infections of these animals can cause severe 
disease, even death, and economic loss to camel owners (29). Racoonpox, skunkpox, 
and volepox viruses are examples of North American OPXVs, but the first genomes 
were only published in 2015 and much yet remains to be discovered about the 
similarities and differences of these viruses in comparison with each other and other 
OPXV (30, 31). Non-North American OPXV species have greater than 90% sequence 








Figure 2.2 Phylogenetic relationship between Orthopoxviruses 
A total of 141 genes were codon-aligned from each indicated orthopoxvirus and used 
for phylogenetic prediction using Bayesian inference by Hendrickson, R. C., et al (4). 
Each branch displays species names, and strain names are provided at each terminal 
node. Numbers at nodes provide the clade credibility values (a measure of the 
confidence of the branching pattern for the indicated clade) for each node. Figure 





2.1.3 Virus Structure 
Poxviruses are brick-shaped viruses larger than most animal viruses. The basic 
infectious form is the intracellular mature virus (MV), but an extracellular enveloped 
virus (EV) form is basically an MV wrapped in an additional cell-derived membrane. 
The basic virus structure as imaged by cry-electron tomography (32) reveals particles 
roughly 360 x 270 x 250 nm with rounded edges. The outer MV membrane is a single 
lipid membrane surrounding two lateral bodies of amorphous structure and an 
hourglass shaped core between them comprised of a proteinaceous wall that encloses 
a nucleocapsid (Figure 2.3, (32)). Deep-etch EM was used to confirm the single outer 
membrane, but does not provide clarification on the presence of a core membrane and 
its structure (33).  
The MV contains about 80 viral proteins (34, 35) although the localization 
and function remains unclear for some. A new analysis software, VirusMapper (36), 
uses super-resolution microscopy to preform single particle analysis and visualize the 
localization of viral proteins within virus particles. Of particular interest, the F17 
protein which along with H1 and G4 is known to be found in the lateral bodies (37), 
was visualized within these structures suggesting this technique could be used to 





Figure 2.3 Cryo-electron tomography of vaccinia virus 
Images were captures by Cyrklaff et al. (32) using cryo-electron tomography of 
intracellular mature vaccinia virus. Images are denoised and surface-rendered viral 
image in A and B to demonstrate the shape and size of the virus. In C and D the 
reconstructed virus is translucent to display the dumbbell-shaped core and internal 






2.1.4 Genome Organization and Nomenclature 
Poxviruses have linear dsDNA genomes that range in size from 134 kbp to more than 
300 kbp (15). By themselves, poxviral genomes are non-infectious, but can be 
rescued by co-infection with an unrelated poxvirus (38). At the ends of the genome 
are hairpin loops that contain inverted terminal repeats (ITRs). Within the ITRs are 
A- and T-rich, incompletely base-paired loops connecting the two DNA strands (39), 
concatameric resolution sequences (40), short, tandemly repeated sequences (41, 42), 
and a few open reading frames (ORFs). Directional deep-sequencing has been used to 
identify replication origins within the ITRs and supports a genome replication model 
utilizing leading and lagging strand synthesis (43). 
 Nearly 100 genes are conserved amongst chordopoxviruses, and about half of 
those are also conserved in entomopoxviruses (Figure 2.4, (44)). Genes are rarely 
overlapping, but can be found running in opposite directions on each strand and ORFs 
tend to point towards the nearest genome end (45). Upstream promotors drive 
transcription at early or post-replicative stages of infection (46, 47). Essential genes 
tend to be located centrally and perform functions essential for replication such as 
transcription, genome replication and assembly. Towards the ends of the genome are 
more variable genes with functions in host defense and interactions (15).  
 The naming of genes or ORFs is based upon fragments of the genome 
resulting from HindIII restriction enzyme digestion of the VACV-Copenhagen strain 





Figure 2.4. Conserved poxviral genes organized by level of conservation 
 
Conserved poxviral genes as organized by Dabrowski, P. W. et al. (25). In the red box 
are those genes found in all poxviruses and represent the highest level of 
conservation. In the green box are genes conserved in all chordopoxviruses, and in 
the orange box are those genes conserved in all orthopoxviruses. Gene names are 
given using the VACV-Copenhagen nomenclature. Figure reprinted with permission 




(48). Within each fragment genes are numbered left to right (except for fragment C 
which is reversed) and ORFs are also given the designation L (left) or R (right), 
depending on the direction (15). For example, A5R is the 5th ORF in the largest 





2.2 Virus Replication 
2.2.1 Attachment and Entry 
Attachment of viruses occurs at the cell surface, with entry through the plasma 
membrane or following endocytosis, with the preferred route of entry varying 
between viral strains and host cell types (15, 49). Vaccinia encodes four proteins 
involved in binding, A26, A27, D8 and H3. A27 and H3 mediate MV entry to cell 
surface via heparin sulfate, D8 can bind chondroitin sulfates, and A26 binds to the 
extracellular matrix protein laminin (50-53). A26 and A27 are tethered to the MV 
surface by the A17 transmembrane protein (54). A27 has also been implicated in 
fusion as co-expression of A17 and A27 at the cell surface can induce cell-to-cell 
fusion (55).  
Twelve addition VACV entry proteins; A16, A21, A28, G3, G9, H2, I2, J5, 
L5, and O3 have been demonstrated to form a complex known as the entry fusion 
complex (EFC). Two additional proteins, F9 and L1, are EFC-associated. The 
structure and protein-protein interactions known within this complex remain limited 
and unclear, and the mechanism of fusion remains unknown (56). Cellular attachment 
molecules have not been identified during the binding of EVs, however, the outer 
viral membrane must be removed following fusion as the EFC proteins are located on 
the MV membrane (15, 57). Entry requires fusion of the viral membrane with either 
the plasma or endosomal membrane. A25 and A26 have been implicated as 
determinants during the entry process as they repress fusion with the plasma 
membrane and in their absence VACV can bypass the low pH requirement (49, 58). 




routes of infection have also been implicated in triggering differential innate sensing 
and signaling within the host cell to restrict infection. For example, in macrophages 
VACV-WR endosomal entry induces IFN-β signaling that can result in an anti-viral 
state (60). 
 
2.2.2 Viral Gene Expression  
Viral gene expression begins almost immediately following VACV entry into the 
cytoplasm and early transcripts can be detected as early as 20 minutes post-infection. 
Expression is temporally regulated (Figure 2.5) with early genes expressed first, 
followed by intermediate and late genes following genome replication. Early 
transcription occurs within activated viral cores as all of the necessary components 
are packaged into the mature viruses. Cores are transported on microtubules to the 
sites of transcription (61). Early transcripts encode enzymes and factors that are 
necessary for genome replication and transcription of the subsequent intermediate 
genes, such as DNA polymerase E9 and intermediate transcription factors A8 and 
A23. Additional early transcripts are involved in the moderation of the host immune 
response.  
All viral mRNAs are both capped and polyadenylated (15). The D5 protein is 
required for genome uncoating, and along with other early protein products, for DNA 
replication (62). Core uncoating signals the switch to intermediate gene expression 
and the decapping enzymes D9 and D10 may play a role in the rapid decline of early 
transcripts (15). In addition, these proteins play a role in the destabilization of host 




complimentary dsRNA (15, 63). The primarily bi-direction synthesis of early 
transcripts toward the nearest end of the genome may also be a mechanism for 
reducing the amount of dsRNA produced during extensive amounts of transcriptional 
activity (45).  
After genome replication, intermediate transcription can occur for enzymes 
and factors necessary for late gene expression. Late genes are transcribed next, and 
continue for the remainder of infection, including structural components of viruses 
and enzymes packaged into infectious particles. These include the multi-subunit 
DNA-dependent RNA polymerase, RNA polymerase-associated protein of 94kDa 
(RAP94), VACV early transcription factor (VETF), capping and methylating 
enzymes, poly(A) polymerase, and topoisomerase, among many others subsequently 
used for early transcription and subsequent genome replication (15). 
 
2.2.3 Genome Replication and Viral Factories 
The poxviral lifecycle occurs entirely in the cytoplasm, however, the process is not 
nucleus independent (64). Replication foci are known as viral factories and appear 
within two hours post-infection (hpi) following VACV infection (65). Recent 
evidence supports a leading-lagging strand synthesis with the origins of replication 
located in the hairpin loop sequences of VACV (43) and is supported by the necessity 
of either virally-encoded ligase or host DNA ligase I (66). Following duplication of 
the viral genome, concatamers are resolved into unit length genomes by the virus-
encoded Holliday junction resolvase (67). Three proteins are essential for DNA 




glycosylase, and each is present in all sequenced poxviruses (15). 
 
2.2.4 Mature Virus Morphogenesis 
The first distinct structures formed in viral factories are crescents (C) that grow into 
complete spherical IVs. These spherical membranes are coated with a honeycomb 
lattice composed of  D13 protein trimers (33) and a dense nucleoprotein (Nu) mass is 
packaged inside the IV before it is completely sealed (68). Seven core proteins are 
required for the filling of IVs, A15, A30, D2, D3, F10, G7 and J1 (69). The major 
transmembrane protein component of Cs and IVs are A14 and A17. Each of these 
proteins can be found in endoplasmic reticulum (ER) and ER-Golgi intermediate 
complex (ERGIC) membranes, interact either directly or indirectly with one another, 
and are phosphorylated by the F10 kinase (70). The N-terminal of A17 interacts with 
the D13 coat and is essential for IV formation (71).  
A new group of viral membrane assembly proteins (VMAP) are conserved in all 
chordopoxviruses and have been identified as essential for poxvirus membrane 
biogenesis: A6, A11, A30.5, H7 and L2. It is suspected that these proteins interact 
with cellular and viral proteins while participating in the disruption of ER membranes 
within factories. These small ER fragments form into Cs and IVs, which is one reason 
why contiguous membranes between the ER and forming viruses have been so 
difficult to image (72, 73). The A32 protein, a possible ATPase, is necessary for 
packaging of the viral genome (74, 75). The I6 protein, a telomerase binding protein, 
also plays a direct and critical role in the genome encapsidation within the viral 





Figure 2.5 Poxviral lifecycle 
The poxviral lifecycle occurs entirely in the cytoplasm of infected cells and is 
carefully regulated to occur in a temporal cascade. Following entry of virus particles 
cores are uncoated and early transcription occurs. Early genes include the DNA 
polymerase subunits, immune defense molecules and intermediate transcription 
factors. Following genome replication intermediate and subsequent late gene 
expression occurs. Late genes include structural proteins and enzymes packaged into 
mature viruses. Virus particles are first visualized as crescent (C) shaped membranes 
that form into complete spherical immature viruses (IVs). Packaging of DNA into IVs 
is followed by maturation events that result in the characteristic brick-shaped 
structure of the infectious mature virus (MV). Some MVs can be wrapped in two 
additional membranes (WVs) and transported via microtubules to the periphery of the 
cell. WVs can bud to become extracellular enveloped viruses (EVs) or polymerize 




hairpins, but is not essential for this early stage of morphogenesis (15, 77).  
Maturation into the infectious MV requires loss of the D13 scaffold via 
cleavage of the A17 membrane protein by viral I7 protease (78). In addition, the core 
proteins A3, A10, A12, L4 and G7 are also proteolytically processed (79). The E10, 
A2.5 and G4 proteins form a unique cytoplasmic disulfide bond pathway, found in all 
poxviruses, and necessary for virus maturation. At least 9 viral proteins have 
intramolecular disulfide bonds formed by the cytoplasmic redox system, including 
L1, F9 and seven EFC members (15, 80). Some OPXVs have the ability to occlude 
MVs in a dense protein matrix within the cytoplasm known as A-type inclusion (ATI) 
bodies. Occlusion requires two proteins: the structural ATI protein, and the A26 
protein anchored to A27 in the MV membrane bridging the connection between MVs 
and ATIs (81). 
 
2.2.5 Extracellular Virus Maturation 
A second form of infectious poxvirus, the EV, is formed after wrapping of an MV in 
two additional membranes to form wrapped virions (WVs), followed by loss of the 
outermost membrane during exit from the host cell to form extracellular enveloped 
virions (EVs). There is good evidence that the membranes wrapped around MVs 
originate from the trans-Golgi network (TGN). Some of the strongest evidence is that 
labeling of WV membranes demonstrates that they contain glycoprotein and 
glycolipid sugars added in the late TGN (82) and when EV proteins are individually 
expressed they can be found within TGN membranes (82-84). The retrograde 




the secretory pathway for transport into the TGN, F13 localization in the TGN is 
blocked when retrograde transport is inhibited. When retrograde transport is inhibited, 
F13 is not found in the TGN and wrapping of MVs is blocked (85, 86). The formation 
of post-Golgi vesicles incorporating B5 and A36 is induced by F13 in the TGN 
through activity of a phospholipase motif (83, 84). Once wrapped, viruses contain 9 
EV-specific proteins: A33 (87), A34 (88), A36 (89), A56 (90), F12 (91), F13 (92), B5 
(93), E2 (94), and K2 (95, 96). 
Wrapped viruses move on microtubules away from viral factories. The A27 
protein on the MV surface is necessary for microtubule movement of MVs out of 
viral factories prior to wrapping (97). Interactions between A36 and the F12/E2 
complex of EVs and cellular microtubule motor kinesin facilitates transport to the 
sites of wrapping (98-100). After wrapping, WVs have three outer membranes. Once 
WVs reach the periphery of the cell the outer viral membrane fuses with the plasma 
membrane and releases double-membraned EVs. Most EVs remain cell-associated, 
but some can form actin tails and protrude away from the host, and yet others can 






2.3 Ectromelia virus and Mousepox Disease 
2.3.1 Introduction 
 Ectromelia virus (ECTV), originally isolated from laboratory mice in 1929 (102), 
causes a smallpox-like disease known as mousepox  (103). Historically, mousepox 
has caused disastrous outbreaks in laboratory colonies (104-106) demonstrating its 
virulence in laboratory mice. The isolation of ECTV from laboratory mouse strains 
during seemingly natural infections (102) demonstrates a matched virus/host model 
not readily and easily available for other OPXVs that do not naturally infect 
laboratory mice (Table 2.2). Similarities between mousepox and human smallpox 
have led to the suggestion that mousepox provides a better model for the evaluation 
of smallpox antivirals and therapeutics then other poxviral models (107-109) making 
it an ideal candidate for the study of poxviral pathogenesis.  
Although multiple ECTV strains have been isolated, the highly virulent and 
highly infectious Moscow strain (72) of ECTV (110, 111) is the most commonly 
studied. The annotated Moscow sequence was first published in 2003 (112) and 
sequence analysis showed 99.5% nucleotide identity with the NAV strain isolated in 
the United States nearly 50 years after MOS, demonstrating the similarity among 
ECTV strains, including the originally isolated Hampstead strain (102). 
 
2.3.2 Susceptible and Resistant Mice 
Much of the early characterization of mousepox was performed using outbred mice, 








Figure 2.6 Timeline of mousepox disease course 
Natural mousepox transmission likely occurs via abrasions in the skin, primarily the 
foot. Viral replication at the site of infection begins almost immediately and spreads 
to the regional lymph node within the first 24 hr. Replication continues in the lymph 
node before the first viremia occurs and the virus enters the blood stream, typically 2-
3 dpi. Virus then reaches the liver and spleen where it continues to replicate and cause 
tissue damage. About a week after infection virus has reached the skin and can begin 
to form visual lesions as it replicates. The infected foot, the site of the primary lesion, 
can also become very swollen and susceptible animals typically succumb to disease 
due to organ failure of the spleen and/or liver at around this time. Animals that 
survive the first 7-14 days will develop a more pronounced rash and full ulcerations 
on the skin. After a few weeks inflammation of the foot decreases and scars are left at 
the site of the primary lesion and pustules from the rash. Reprinted with permission 




post-infection (DPI) (Figure 2.6) with extensive necrosis of the liver and spleen; and a 
chronic form presenting with ulcerative lesions on the feet, tail and snout (102, 114). 
Eventually, these separate disease courses were identified as susceptible and resistant 
mousepox, respectively, and not representative of separate diseases but rather 
different outcomes of mousepox. Both disease outcomes occur following high viral 
titers in the spleen and liver, and death is primarily due to high viral doses in these 
organs. In contrast, animals that survive eventually developed the whole body rash 
following control of virus in the spleen and liver (115-117).  
Disease patterns were further characterized using inbred mouse strains and 
found to be greatly influenced by the genotype of the mouse (118). Clinical disease 
has also been found to be more severe in very young suckling mice and older mice 
(one-year old) than in adult 8-week-old mice (119), as well as shorter time to death in 
male mice over female (115) suggesting that immune fitness and hormones may play 
a role in virulence. 
 
2.3.3 Footpad Model 
Epizootic infections of ECTV are seemingly indistinguishable from footpad 
inoculation or scarification (120) and have led to the suggestion that the natural route 
of transmission from animal-to-animal occurs through small abrasions of the skin 
(103, 111). Infection by intradermal injection of a small volume (typically 10-100 µl ) 
into the rear footpad is most commonly considered the best mimic for natural 
mousepox transmission and has been the most extensively characterized (Figure of 




The following are descriptions of the disease progression following footpad 
infections in susceptible mouse genotypes, typically resulting in death from acute 
mousepox 7 to 10 DPI (120, 122). 
 
2.3.4 Primary Lesion 
Following infection, the first infected cells are either dermal cells or cells in the 
Malpighian layer of the epidermis followed by local replication in the epidermis 
which forms the primary lesion (123). Intradermal innocula have also been shown to 
enter the lymphatics almost immediately following inoculation (124). The primary 
lesion that develops at the site of infection consists of localized swelling that rapidly 
increases in size with pronounced edema due to cutaneous anaphylaxis (123) and is 
usually punctuated by a minute breach of the skin (120). About 7 DPI swelling of the 
infected foot becomes visible (Figure 2.6) and virus can be found at high 
concentrations. Swelling and edema quickly increases reaching a maximum at about 
day 10. There may be A type inclusions (ATIs) of occluded infectious virions in the 
epidermal cells or lymphatic infiltrations of the dermis. If the mouse survives, a hard 
adherent scab will form following ulceration, and drop off to reveal a permanent scar 
on the foot after 7 to 14 days (122).  
 
2.3.5 Lymphatic Involvement 
During the 4-6 day incubation period, virus replicates locally in the development of 
the primary lesion, as well as within the spleen and liver. Subsequent disease course, 




of virus replication in these organs. Spread from the primary lesion into the 
lymphatics often occurs via macrophages causing a sequential infection of local 
lymph nodes and internal organs known as “primary viremia”. Regional lymph nodes 
draining the primary lesion become enlarged and necrotic (122), and serve as sites for 
viral replication, including the presence of numerous ATIs. Necrosis of the lymph 
nodes can be attributed directly to viral replication, but may also be due to the stress 
caused by severe mousepox disease (125, 126).  
 
2.3.6 Spleen and Liver 
Subsequent lympho-hematogenous spread from lymph nodes into the liver and spleen 
occurs early, prior to establishment of adaptive immunity, and more slowly in 
resistant mice than susceptible mice (127, 128), suggesting differences in innate 
immune responses to infection. Virus reaches the spleen via infected lymphocytes 
where it replicates and maintains very high titers (up to 1010 PFU/g tissue) until death. 
Infiltrating infected lymphocytes infect splenic follicles that undergo necrosis and 
result in the characteristic mottled spleen of mousepox. The liver is also infected 
during acute mousepox, along with pronounced hepatosplenomegaly (118, 129).  The 
phagocytic Kupffer cells of the liver appear to be infected first, followed by the 
parenchymal cells (130). Viral loads in the liver are typically lower than the spleen, 
and appearance of the liver is relatively normal, until the day of death when the liver 
becomes enlarged and studded with white foci representing hepatic necrosis and viral 





2.3.7 Secondary Viremia  
Secondary viremia is the result of virus, primarily from the heavily infected spleen 
and liver tissue, being released into circulation. It can cause infections of the skin and 
sometimes kidneys, lungs and intestines. Intestines are often engorged and sometimes 
necrotic (117). Kidneys and bladder can be necrotic and sometimes hemorrhagic in 
very young mice. Virus is detectable in the blood at titers up to 104 PFU/mL on day 8 
or 9. Histologically, virus can be detected in low levels within most tissues at this late 
stage, including: bone marrow, nasal mucosa, ovary, vagina, uterus, etc. (116).  
 
2.3.8 Secondary Rash 
Although virus titers in the skin are often elevated, high viral loads of the spleen and 
liver can cause death prior to visible lesion formation (122). In surviving animals, 
virus deposited in the skin eventually develops into a multifocal necrotic rash known 
as the secondary rash, the severity of which is dependent on the degree of viremia 
(129). The secondary rash appears 2 to 3 days after the primary lesion (9-11 DPI, 
Figure 2.6) as raised, slightly pale areas. As these areas of proliferation and edema 
increase in size they may become visible as slightly raised macules. Numerous ATIs 
are present in epidermal cells and lesions develop epidermal necrosis of the 
superficial cells. Widespread inflammatory edema and lymphocytic infiltration of the 
dermis accompanies massive necrosis, and animals will develop papules that close 
over with scabs during healing. The presence of conjunctivitis commonly 
accompanies the rash. Animals that die of acute mousepox frequently succumb 




roughly 9 to 11 DPI (122). 
 
2.3.9 Intranasal Innoculation  
Intranasal infection of susceptible mice has also been studied as ECTV was 
historically unintentionally passaged along with influenza virus, developing into a 
generalized mousepox disease. Low inoculum volumes result in local upper 
respiratory infections with minimal lung involvement, death results from necrosis of 
the liver (103), and high viral loads have been reported in the spleen. Larger volumes 
(greater than 10 µl) can result in congestion of the lungs and lead to pneumonia. 
BALB/c mice were approximately 100-fold more resistance to the intranasal route 




2.4 Host Immune Responses and Poxviral Evasion Mechanisms 
The large size of poxviruses allows for the inclusion of many different genes that 
encode for proteins capable of interacting with and modulating the immune response 
(Figure 2.7). Due to selection pressure, by diverse host immune responses, these 
genes are more often mutated between species and can be highly specific in target or 
function. In some cases, proteins can also be multifunctional and/or capable of 
regulating the host immune response at multiple stages. Together with the complexity 
of the host immune response, this can be a challenging puzzle to break apart and 
understand, but it is critical for medical and research professionals that the role of 
defense proteins from both host and pathogen are well understood. 
The mousepox infection model provides a naturally matched virus-host model 
for the study of the host immune response and viral defense mechanisms, which 
compete against each other. It has been clearly demonstrated that resistance to 
mousepox requires a strong polarized type 1 immune response. Thus the NK cells, 
CTLs, and IFN-gamma responses are especially important for survival, although not 
the only components of the immune system modulated by the virus, suggesting that 
the immune response and modulation by the virus is highly complex. Reviewed 
below is a selection of some of the important viral-host interactions during poxvirus 
infection with some important ECTV proteins important during mousepox disease 
highlighted. 
2.4.1 Immune Sensing Mechanisms  




recognize Pathogen Associated Molecular Patterns (PAMPs) such as double-stranded 
RNA (dsRNA), lipopolysaccharides and nucleic acid variants, among others. The first 
PRRs discovered were membrane-associated toll-like receptors (TLRs) on both cell 
surfaces and endosomal membranes. There are also cytosolic RNA sensors like RIG-
I-like receptors (RLRs), including retinoic acid inducible gene I (RIG-I) and 
melanoma differentiation antigen 5 (MDA5); as well as cytosolic DNA sensors such 
as absent in melanoma 2 (AIM2), cyclic GMP-AMP synthase (cGAS) stimulator of 
interferon (IFN) genes (STING), DNA dependent protein kinase (DNA-PK), and 
DNA-dependent activator of IFN-regulatory factors/Z-DNA-binding protein 1 (DAI) 
(132).   
 Similar to PRRs, host cell inflammasomes are multimeric cytosolic sensors of 
infection that recognize conserved molecular components. Some inflammasomes are 
composed of nucleotide-binding domain, leucine-rich repeat and pyrin domain 
containing protein (NLRP) and contain caspase 1. Proteolytic activation via caspase 1 
results in active IL-1β and IL-18, pro-inflammatory cytokines with antiviral 
properties. (133, 134). 
 
2.4.2 Evasion of Innate Sensing and Activation of NF-ĸB 
To counteract host cell PRR sensing and subsequent events poxviruses possess their 
own set of intrinsic immunomodulatory proteins capable of blocking host cell 
immune sensing events at multiple stages. First, poxviruses can block the binding of 
PAMPs to the sensing receptors. The C-terminus of E3 contains a Z-DNA-binding 




136). DNA-PK, a PRR for IFN-regulatory factors (IRF) 3-dependent innate 
immunity, is bound by C16 and can block sensing of DNA in the cytoplasm (137).  
A second strategy of poxviruses to evade the host immune response is to 
inhibit downstream signaling pathways of PRRs, and VACV has evolved many 
mechanisms for blocking these pathways. VACV A46 is capable of binding multiple 
Toll/IL-1R (TIR) domain-containing adaptor molecules including myeloid 
differentiation primary response gene 88 (MyD88), MyD88 adaptor-like (MAL), 
TIR-domain-containing adaptor-inducting IFN-β (TRIF) and TRIF-related adaptor 
molecule (TRAM) all of which associate with the cytoplasmic tails of TLRs (138, 
139). This inhibitory capacity allows blocking of multiple IFN-β inducing pathways. 
The A52 protein acts by binding and inhibiting IL-1R-associated kinase 2 (IRAK2) 
and tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) (138, 140) just 
downstream of A46 targets.  
The structure of A52 has been revealed as a B-cell lymphoma 2 (Bcl-2) –like 
fold (141) containing protein, a structure conserved among multiple other VACV 
proteins that inhibit the host innate immune response and/or apoptosis, including: 
A46, A49, A52, B14, C1, C6, C16, F1, K7, N1, and N2 (142-145). The K7 protein 
binds IRAK and TRAF6 preventing nuclear factor kappa-B (NF-ĸB)(146) and the 
DEAD-box RNA helicase 3 (DDX3) preventing IRF3 activation via the kinases 
TANK-binding kinase 1 (TBK1) and IKKɛ (147), kinases that act at the convergence 
of several IRF3 activation pathways. VACV C6 also interacts with scaffold adaptor 
proteins for TBK1/ IKKɛ to inhibit IRF3 and IRF7 activation (148). Lastly, the 




the mechanism remains unknown (149). 
The NF-ĸB pathway in host cells can also be activated by IL-1- and TNF-
mediated signaling which converges at the inhibitor of ĸB kinase (IKK) complex. 
Viral proteins that inhibit the IKK complex directly include N1 acting at the dimer 
interface (150), B14 binding IKKβ and blocking phosphorylation of the inhibitor of 
ĸB (IĸBα) (151), and C4 whose mechanism is unknown (152). A49 has been shown 
to stabilize IĸBα through molecular mimicry preventing its ubiquitination and 
degradation in the proteasome thus trapping NF-ĸB in the cytoplasm (153). The K1 
protein may have a similar function although the mechanism remains unclear (154), 
and M2 reduces extracellular signal-regulated kinase 2 (ERK2) phosphorylation and 
p65 translocation (155, 156).  
NF-ĸB is a potent mediator of anti-viral immunity and so it is not surprising 
that ECTV, like other poxviruses, encode many proteins to help modulate the activity 
of this cellular response. ECTV002 inactivates NF-ĸB subunit p105 (157, 158) and 
reduces expression of proinflammatory cytokines in vivo leading to attenuation in 
BALB/c mice. Interestingly, C57BL/6 mice deficient in IRF7 but not MyD88 or 
TLR9 also are attenuated when infected with this mutant virus (158) suggesting that a 
cross-talk between T1-IFN (Type 1 interferon) and NFkB signaling pathways 
contribute to resistance to mousepox (158). ECTV150 is a BTB/kelch protein that 
inhibits NF-ĸB signaling through inhibition of p65 translocation (159). The VACV 
K1 protein has also been shown to inhibit NF-κB by preventing IĸBα degradation 





Cooperatively these mechanisms provide a profound block on IFN-β 
production by poxvirus-infected cells through the blockage of IRF3 and NF-ĸB 
activation. However, the production of IFNs by neighboring infected or uninfected 
cells can still induce an anti-viral state that can inhibit poxviruses. 
 Infected cells, such as CD11b+ inflammatory monocytes in the draining LN, 
produce T1-IFNs and ISGs dependent upon STING, indicating the need for cytosolic 
PRR recognition of PAMPs for T1-IFN production following ECTV infection (158, 
160). However, other PRRs such as TLR9 (but not other TLRs), its adapter MyD88, 
and downstream components IRF7 and NFĸB, when deleted in B6 resistant mice 
result in mousepox susceptibility (158, 161, 162). Two separate PRR pathways act to 
indirectly (TLR9-MyD88-IRF7) and directly (STING-IRF7/NFkB) induce T1-IFN 
expression by inflammatory and infected monocytes, respectively, and thus control 
and protection against mousepox (163). 
 
2.4.3 Interferon Production and Interferon Stimulated Genes 
Each of these PRR receptor families induces signaling cascades culminating in the 
activation of transcription factors such as NF-ĸB, IRF3 and IRF7, and activator 
protein 1 (AP1) that lead to the production of inflammatory cytokines and type 1 
IFNs (T1-IFN), IFN-α and IFN-β (164). In contrast, IFN-γ, the only T2-IFN, is 
produced by activated natural killer (NK) cells and activated T cells (165).  
Receptor binding of T1-IFNs to the IFN α/β receptor (IFNAR) results in 





Figure 2.7 Vaccinia virus immune modulatory proteins interact with host signalling 
cascades. 
This comprehensive figure compiled by Perdiguero, B. and Esteban, M. (166) shows 
the complicated interplay between host defense molecules and viral immune 
modulators. At the top are pattern recognition receptors TLR, RLR, NLR, and 
cytoplasmic sensors, which when stimulated by their associated PAMPS initate 
downstream signalling cascades. Viral immune modulator proteins are shown in red 
boxes at the points where they can interact along these cascades. Key transcription 
factors such as NF-ĸB, IRF3 and IRF7 are activated by these signaling cascades and 





(STAT) pathway and transcription of hundreds of IFN-stimulated genes (ISGs) (165). 
Some ISGs, protein kinase R (PKR), 2′-5′-oligoadenylate synthase (OAS), ISG15 and 
Mx proteins can confer an antiviral state. For example, activation of OAS by dsRNA 
leads to the activation of RNAse L, which is capable of degrading viral and cellular 
mRNAs (167). When activated by dsRNA, PKR autophosphorylates and can 
phosphorylate eukaryotic translation initiation factor (eIF2α) resulting in the cessation 
of protein translation. Other ISGs include PRRs (such as RIG-I) and IFN-response 
signaling factors (such as IRFs and STAT1) that assist in the detection and 
amplification of the IFN-response in infected and neighboring cells (168). Together, 
ISGs are important for the amplification and regulation of the IFN response and other 
mechanisms that interfere with the viral life cycle. 
 
2.4.4 Inhibition of Interferon Stimulated Genes 
Poxviruses employ a variety of strategies to inhibit the anti-viral effects of IFNs. The 
previous sections described methods employed by poxviruses to reduce the 
production of T1-IFNs through the blockage of innate sensing, but poxviruses also 
block IFNs from reaching their receptors, blocking IFN-induced signal transduction, 
dephosphorylating signaling molecules, and inhibiting the expression and action of 
IFN-response genes.  
Lateral bodies may serve as immediate delivery packets for viral defense 
molecules as they break away from the cores early during infection. Known proteins 
include F17, which dissociates in the reducing environment of the cytoplasm, and the 




determined, vH1 dephosphorylates STAT1 and STAT2 thus inhibiting signaling from 
all IFN receptors (37, 169).  
The shutdown of host protein synthesis by decapping enzymes D9 and D10 is 
both fast and highly efficient and contributes to the reduced production of ISGs (170, 
171). These enzymes also reduce the accumulation of dsRNA and thus reduce sensing 
via the ISGs PKR and OAS (63, 172). The previously mentioned E3 protein binds 
dsRNA preventing sensing by PRR but also PKR and OAS. In addition, the K3 
protein, which has amino acid similarity to eIF2α, functions as a non-
phosphorylatable substrate for PKR and competitor with eIF2α (173).  
 
2.4.5 Interferon Decoy Receptors 
The production of decoy receptors also provides an effective strategy used by 
poxviruses to block IFNs. T1-IFNs can be inhibited by the early protein, B18, both on 
the cell surface and in solution (174, 175). B18 binds T1-IFNs from a wide range of 
species (176), however, it only inhibits IFN-α efficiently. Inhibition of IFN-β by 
poxviruses relies primarily on intracellular mechanisms such as disruption of innate 
sensing and downstream signaling molecules (177). A soluble T2-IFN decoy receptor 
is encoded by the poxvirus B8R gene and binds IFN-γ outside of cells. Interestingly, 
B8 protein can dimerize unlike cellular IFN-γ receptor, but it lacks the 
transmembrane and cytoplasmic domains (178, 179). Like B18, the B8 protein has a 
broad host range (180). A variety of poxviruses also express decoy receptors targeting 
IL-18 (181), and TNF (182) receptors. 




known (183). T1-IFNs and ISGs appear first in the draining LN then in the liver 
coincident with viral spread (184), indicating that these factors are produced in 
infected tissues and not present due to systemic distribution. When infected, ECTV 
spreads faster to the spleen and liver in 129 mice deficient in cellular IFNAR1, 
demonstrating that early T1-IFN and ISG production is important for viral control and 
subsequent survival (158, 163). When anti-T1-IFN antibodies were given following 
footpad infection to resistant C57BL/6 mice it was found that depleting IFN-alpha 
had no effect on organ titers, but IFN-beta was important for viral clearance in the 
liver and not the spleen. Either treatment resulted in only 25% mortality (185). High 
levels of IFN-α2 binding has been detected on the surface of ECTV-infected cells 
(186) and an inhibitor of IFN-α activity can be found in cellular supernatants (187).  
ECTV166 is a secreted T1-IFN decoy receptor and deletion of ECTV166 
from ECTV attenuates mousepox in BALB/c mice. Death of RAG-1 deficient mice 
(which lack adaptive immunity) following footpad infection by an ECTV166 deletion 
virus indicates a role for the adaptive response in the protection of T1-IFNs (188). 
Furthermore, ECTV166 depletion by antibody after infection results in restoration of 
T1-IFN signaling in livers and allows survival in susceptible mice (184). Thus, ECTV 
must effectively control T1-IFN responses for lympho-hematogenous spread and to 
protect the liver, the likely cause of death from mousepox. Interestingly, the ECTV 
vT1-IFN receptor has been shown to inhibit both human and mouse IFN-α, but only 
human IFN-β (187, 188). 
Unlike the modest role of T1-IFNs during recovery of C57BL/6 mice from 




replication especially in the liver, spleen, ovaries and lungs (185). Part of the activity 
of IFN-γ is mediated through nitric oxide production, a critical component in the 
inherent resistance to mousepox (189). As IFN-γ is a critical component in the 
activity and promotion of a type 1 immune response these data serve to underscore its 
importance during control of ECTV infection. Efforts by the virus to this effect 
include expression of an IFN-γ decoy receptor (ECTV158) that when deleted from 
the virus during infection allows for more IFN-γ production by the infected animal. 
Susceptible BALB/c mice infected with the mutant virus were shown to be able to 
control replication and survive the infection (190), however the extent of this 
attenuation remains somewhat controversial (191, 192). An increase in the percentage 
of IFN-γ producing CD8+ T cells in the draining LN and spleens of resistant 
C57BL/6 mice early after infection further supports the importance of an early IFN-
gamma response (193).  
 
2.4.6 IL-1 Family Cytokine Responses 
The innate inflammatory response against viral infection is amplified by cytokines 
such as TNF-α, IL-1 and IL-18. In addition, these cytokines can directly induce 
apoptosis of infected cells via TNF-α and influence the developing adaptive immune 
response. OPXVs have evolved multiple strategies for the inhibition of these key 
cytokines including additional decoy receptors, precursor processing inhibitors, and 
downstream signaling inhibitors.  
 The IL-1 protein is synthesized as pro-IL-1β following NF-ĸB activation and 




strategies already discussed, VACV is capable of blocking caspase 1, and IL-1 
maturation, by inhibiting the activation of inflammasomes. The F1 protein also 
interacts with NLRP inflammasomes and reduces active IL-1β and IL-18 production 
(134). Two forms of IL-1, α and β, generally overlap in function as they each interact 
with the same cellular receptors. Ectromelia-infected cells secrete a vIL1β protein 
receptor (homologous with B15 in VACV (175)) with similarity to the extracellular 
domain of the type II TNFR. This mock receptor inhibits binding of mouse and 
human IL1β to the cellular receptor. Unlike cellular receptors, vIL1β shows no 
binding activity with IL1α (194, 195). Details on the contribution of vIL1β to 
pathogenicity during mousepox has not been demonstrated, but deletion from VACV 
does result in increased morbidity intranasally (175) and decreased pathogenicity 
following intracranial infection (196). 
 IL-1 and IL-18 (discussed below) require cleavage of premature cytoplasmic 
forms by caspase 1 to become mature and active in modulating the immune response. 
ECTV-encoded serine protease inhibitor (serpin) SPI-2 (homologous with B13 in 
VACV) has been shown to inhibit caspase 1 and 8 and thus TNF-mediated apoptosis, 
which also utilizes caspase 1 (197). Although not demonstrated in ECTV, the 
cytokine response modifier A (CrmA) CPXV homolog can block the processing and 
release of both IL-1β and IL-18 in CPXV or VACV (195, 198-200). The role of SPI-2 
in pathogenesis during mousepox infection remains to be determined. 
IL-18 is a member of the IL-1 family of cytokines, expressed in the epidermis, 
and has potent pro-inflammatory potential through its induction of other cytokines. 




similarity to IL-18 BPs of other poxviruses, and that has been shown to reduce NK-
cell activity and IFN-γ levels after infection (201, 202). Mousepox resistant C57BL/6 
mice altered to become deficient for IL-18 or IL-12p40, both important for IFN-γ 
production, had reduced CD8+ T cells at the site of infection and increased splenic T 
regulatory cells following ECTV infection. When both IL-18 and IL-12p40 were 
depleted, C57BL/6 mice became susceptible to mousepox via reduced NK and CTL 
responses (203).  
 
2.4.7 Tumor Necrosis Factor α 
TNF-α is another important early cytokine mediator of the immune response that acts 
via the type I (p55) or type II (p75) TNF receptor (TNFR) thought to be produced 
predominantly by macrophages and activated T cells. It can induce an antiviral state 
in uninfected neighboring cells, selective cytolysis of infected cells, apoptosis, and 
recruit lymphocytes to the site of infection (204). Production of TNF is also inhibited 
as it is an NF-ĸB target gene. When resistant mice deficient in both TNFRs are 
infected they become susceptible to lethal infection by ECTV and it was determined 
that both receptors are necessary for resistance (205). 
Orthopoxviruses encode four vTNFR decoy receptors: CrmA, CrmB, CrmC 
and CrmD. Ectromelia virus encodes only one full length vTNFR, CrmD (195, 206) 
and a second, truncated vTNFR, CrmE (207). Although uncharacterized, CrmC is 
also fragmented in ECTV, and the CrmB appears to be missing although ORF 008 
may be related (42% similarity) (112). Interestingly, an additional secreted member 




inflammation in vivo (208), but was determined not to be a major virulence factor 
during mousepox (209). 
 
2.4.8 Other Important Cytokines 
The expression of cytokines can influence the type of adaptive immune response 
generated against infection and can have drastic effects on the outcome of disease. 
Some cytokines like IL-4 or IL-6, part of a type 2 immune response, reduce the 
cellular immune response, reduce anti-viral cytokine expression, and can increase the 
virulence of VACV (210, 211). Others like IL-2 and IFN-γ, characteristic of a type 1 
immune response, can reduce the virulence of VACV by stimulating the activation 
and proliferation of NK cells and T cells (212, 213). IL-6 along with IL-17 has been 
shown to inhibit the protective effects of CTLs during viral infection (211). In 
susceptible BALB/c mice IL-6 dependent activation of STAT3 does not occur, as it 
does in resistant C57Bl/6 mice that rapidly activate both STAT1 and STAT3. These 
evidence suggest that IL-6 is necessary for the survival of mousepox (214). 
 
2.4.9 Chemokine Responses 
Chemokines are a class of chemoattractant cytokines that recruit leukocytes to sites of 
cellular stress, such as viral infections (145). Circulating leukocytes detect chemokine 
gradients on endothelial surfaces used to direct them to the site of infection. There are 
a variety of different chemokines produced by different cell types and with different 
chemokine receptor specificities that fine tune the inflammation response. 




CXC. VACV has evolved several methods to inhibit the production or function of 
chemokines including inhibition of their expression due to NF-ĸB and IRF3 
activation. VACV also expresses chemokine-binding proteins (vCKBP) including CC 
chemokine inhibitor (vCCI) that binds a range CC chemokines with high affinity and 
is secreted by infected cells early during infection (215). A similar protein, A41, also 
binds chemokines (CCL21, CCL25, CCL26 and CCL28) although with lower affinity 
and it does not inhibit chemokine receptor binding. However, heparin binding 
competes with A41 binding, suggesting that its mechanism of action is via disruption 
of the chemokine concentration gradient on endothelial cells (216). 
 The most abundant secreted protein of ECTV is the vCKBP, vCCI, with no 
sequence similarity to cellular chemokine receptors, although it is well conserved 
amongst poxviruses (195, 217). Activity in mousepox has not yet been evaluated, but 
during rabbitpox or myxoma virus infection lack of vCCI results in reduced leukocyte 
infiltration at the site of infection (218, 219) and has been structurally demonstrated 
to bind CCL2, CCL3 and CCL5 (220). 
In addition to the highly conserved vCKBP, the ECTV-Nav E163, a VACV 
A41 homolog, protein has been shown to bind the glycosaminoglycans on 
chemokines, including CXCL10 and CXCL12α with high affinity and inhibit the 
chemokine-induced leukocyte migration to the sites of infection via disruption of the 
chemokine gradient (221). 
 
2.4.10 Complement Control 




can bind the virally encoded complement control protein vC3, a protein capable of 
inhibiting the complement cascade by binding host C3a and C3b (223). It is possible 
A56 could have a similar role on the EV surface. The virus also incorporates the host 
proteins CD46, CD55, CD59, CD71, CD81 and MHC class I molecules into EVs. 
Both CD55 and CD59 are complement control proteins and when incorporated into 
VACV EVs reduces the efficacy of human complement control (224). 
 Recovery from mousepox requires the complement control system. When C3, 
a central component of the complement cascade, was absent resistant C57BL/6 mice 
had increased viral dissemination and mortality. Sera deficient in components of 
either the classical or alternative pathways had reduced capacity to neutralize virus 
particles suggesting both pathways play a role in viral pathogenecity (225).  
 
2.4.11 Regulation of Apoptosis 
Apoptosis is the controlled cell death induced by the sequential cleavage of caspase 
proteases and is a powerful mechanism for the elimination of virally-infected cells. 
The process is controlled by a balance of pro-apoptotic and anti-apoptotic members of 
the cellular Bcl-2 family of proteins. Pro-apoptotic proteins, such as Bid or Bad, bind 
effector proteins Bak and Bax on the outer membrane of the mitochondiria and 
induce the release of cytochrome c into the cytoplasm and the formation of the 
caspase activation platform or apoptosome. As caspase 1 is one of the modulators of 
the apoptotic response, production of SPI-2 inhibits apoptosis in addition to its role 
inhibiting pro-IL-1β cleavage (197). The SPI-2 protein (also known as CrmA) can 






Figure 2.8 Schematic representation of immune response against pathogens 
The adaptive arm of the immune response is a complex network of signals and 
responses. Simply, pathogens can be picked up and processed by antigen presenting 
cells, like the dendritic cell depicted here, for presentation to naïve T cells. B cells can 
also recognize pathogens via their B cell receptor (BCR) and with the help of T cells 
become activated, expand, and adapt as they produce antibodies. T cells, once they 




(Th2) helper cells, driving an antibody and B cell driven response (Th2) or cytolytic 
T cell and cell-mediated response (Th1). This response is driven in part through the 
production of distinct cytokines: IL-4, and IL-10 are primarily Th2 drivers and will 
produce IL-4, IL-10 and IL-13; IL-12 and IFN-γ are primarily Th1 driver and will 





inhibitor, SPI-1, blocks apoptosis via a caspase-independent pathway by inhibiting 
cathepsin G (227, 228). 
 Poxviral proteins F1 and N1 both adopt a BCL-2-like fold (229, 230). F1 
binds the NLRP-1 protein thus inhibiting the inflammatory response and apoptosis, as 
NLRP-1 is an upstream activator of caspase 1 (134). The N1 protein binds pro-
apoptotic Bcl-2 proteins Bid and Bad to inhibit apoptosis (150).  
 
2.4.12 Natural Killer cells 
Natural killer (NK) cells are a specialized subtype of granular lymphocytes with high 
cytolytic activity against virus-infected and tumor cells. As an important component 
of the innate immune response, they form a primary defense against viral infections 
before the adaptive arm of the immune response fully develops. NK cell activation is 
dependent on cytokines such as IFN-α, IFN-β, IL-12 and IL-18, but cytolytic activity 
is regulated by a variety of activating and inhibitory receptors on the surface of target 
cells (231). Most NK inhibitory signals recognize MHC class I molecules ensuring  
tolerance against self-antigens. Activating receptors are often natural cytotoxicity 
receptors such as NKp46, NKp44, NKp30 as well as CD16 and NKG2D (232).  
It is well known that NK cells are important immune components in response 
to poxviruses as they are essential for C57BL/6 resistance against mousepox. When 
NK cells are depleted it also increases susceptibility to VACV (233, 234). Infection 
with VACV increases susceptibility to NK lysis (235) following downregulation of 
MHC class I (236), but cytotoxicity can be attributed directly to downregulation of 




class I downregulation is quite variable between poxviruses (239). Protein CPXV012 
impairs ER peptide loading and dissociated of MHC class I from transporter 
associated with antigen processing (TAP) protein (240). Protein CPXV203 sequesters 
MHC class I molecules in the ER using its C-terminal KDEL-like sequences (241). 
The VACV A56 protein has also be identified as a novel viral ligand for activating 
receptors NKp30 and NKp46 (242). Some orthopoxviruses, including CPXV and 
MPXV, encode a protein that resembles an MHC class I molecule (OMCP) that can 
block the recognition of host ligands and inhibit NKG2D-dependent NK lysis (243). 
 NK cells were first identified as important for ECTV susceptibility via genetic 
analysis (244), (next section). However, studying the role of NK cells by antibody 
depletion or genetic mutations is complicated as these approaches can have off target 
effects on NKT cells when using NK1.1 antibody (245), CD8+ T cells when using 
anti-asialo GM1 (183, 246), or granule exocytosis in bg/bg mutant mice (183).  When 
C57BL/6 mice are infected with ECTV, NK cells but not NKT cells, are crucial for 
the recovery from mousepox. NK cells have been shown to proliferate, accumulate, 
and are activated in the spleen and liver of virus-infected mice (247). Protection in 
C57BL/6 mice via NK cell activity is suggested to occur through two mechanisms; 
first, the reduction of lympho-hematogenous spread of virus from LN to spleen is 
reduced through NK cell perforin cytotoxicity and IFNγ production (248), and 






2.4.13 Adaptive Responses  
Following the non-specific innate immune response there is a delayed, target-specific 
immune response known as the adaptive arm of immunity (Figure 2.8). Adaptive 
responses are not only antigen specific, but they can adapt, improve, and provide 
lasting, long-term immunity to protect against re-infection. To assist in this 
specialized response, innate factors can influence the adaptive responses for 
optimized effect. With the help of activated CD4+ T helper cells, B cells produces 
virus-specific antibodies capable of neutralizing extracellular viruses, and CD8+ 
cytotoxic T cells (CTLs) are capable of direct virus-infected cell killing. Both arms of 
adaptive immunity are induced by VACV infection with CD4+ T cell-dependent 
antibody responses being most important for viral clearance and CTLs controlling 
disease severity and mediating protective memory upon reinfection (249-251). Key 
cytokines like TNF-α, IL-1β, IL-4, and IFN-γ control adaptive responses in addition 
to their roles during inflammation. Thus, the methods of controlling these cytokines 
also influence adaptive immune responses. 
 
2.4.14 Antigen Presentation and T Cell Help 
In order to develop a target-specific response, adaptive immune cells must encounter 
pathogen-specific sequences known as antigens in a stimulatory environment. 
Antigen presenting cells (APCs) such as dendritic cells (DCs) collect pathogenic 
material by phagocytosis for display to B cells and T cells via MHC molecules. CD4+ 
T cells recognize peptides bound to MHC class II molecules of professional APCs via 




Depending on the cytokine environment they are in, CD4+ T helper (Th) cells will 
differentiate into Th1 cells (primarily stimulated by IFN-γ and IL-12), or Th2 cells 
(stimulated by IL-4 and IL-10). Th1 cells will drive a primarily cellular adaptive 
immune response through the production of IL-2, IFN- γ and TNF-α, utilizing CD8+ 
cytolytic T cells (CTLs). Th2 will drive a humoral response of B cells and antibody 
through the production of IL-4, IL-10 and IL-13. Th cells can also differentiate into 
effector, memory or regulatory Th cells (252). The different types of activated CD4+ 
T cells have a variety of roles within the host immune response, including: the 
priming of CD8+ T cells, B cells, cytokine production and direct cytolytic activity 
(253).  
The priming of B cells and CD8+ T cells in response to viral infections 
typically requires CD4+ Th cell help to direct and maximize the response (254). 
Following VACV infection the degree of CD4+ Th cell help-dependence is also 
dependent on the route of infection and dependence is increased at lower viral doses 
(255). Infected antigen presenting cells can also directly present antigen via MHC 
class I molecules to CD8+ T cells, and indeed this direct presentation has been shown 
to be a major source of CTL activation by VACV-infected cells (256, 257). Some 
leukocytes can be directly infected by poxviruses during infection, including B and T 
lymphocytes, NK cells, dendritic cells and monocytes/macrophages (143). This 
infection can contribute to the direct presentation of viral antigens to CTLs by APCs, 
despite the fact that infection does not induce maturation in dendritic cells (258), and 
the counteractive downregulation of MHC molecules by viral factors in infected cells.  




cell memory, CD4+ T cells can also have direct influences on the adaptive immune 
response through the production of cytokines (like IFN-γ)  and via target cell lysis 
(253). As poxviruses, and VACV in particular, are of interest as vaccine vectors the 
role of Th cells in the development of protective immunity has been an area of intense 
interest. Extensive work has been conducted to identify the epitopes utilized during 
the immune response and at least 246 distinct epitopes restricted by MHC class I and 
61 restricted by class II have been identified. However, only nine different antibody 
epitopes have been mapped (249). Achieving a better understanding of these epitopes 
can help us to understand how the immune response is directed against poxviruses 
and vaccine vectors and, hopefully, help to improve their efficacy (259). 
 
2.4.15 Role of CD4+ T Cells During Disease 
T cells have been well established as essential for the control of ECTV infection, 
even in animals who would be otherwise resistant. When C57BL/6 mice were treated 
with antithymocyte serum they succumb to mousepox infection (260), and adoptive 
transfer of effector splenocytes can decrease viral loads in the absence of 
antithymocyte serum (261).  
CD4+ T cells have a variety of roles within the host immune response 
including the priming of CD8+ T cells, B cells, cytokine production and direct 
cytolytic activity (253). For these reasons it can be challenging to determine the exact 
role of CD8+ versus CD4+ T cells and other immune cells that rely heavily on each 
other for their activities. Nonetheless, the role of CD4+ T cells is essential for control 




absent during primary infection, mousepox disease lasts for extended periods of time 
(246). Although somewhat controversial, it appears that CD8+ T cell priming and 
CTL response are largely independent of CD4+ T cell help or CD40-CD40L 
interactions (262-264). However, the helper function of CD4+ T cells is still required 
for priming of B cells by CD40-CD154 costimulation (265), and a similar delay in 
death is observed in the absence of B cells or antibody (20-90 DPI) as in the absence 
of CD4+ T cells (163, 266). There are some studies suggesting that CD4+ T may 
have an additional cytolytic role during infection. CD4+ T cells expressing granzyme 
B have been found in the popliteal LN and liver, and when CD4+ T cells are deficient 
in Prf animals had reduced viral control (267). 
 
2.4.16 CD8+ T cells and the Cellular Response 
CD8+ T cells are stimulated through recognition of foreign antigen presented on the 
surface of infected cells via MHC class I molecule interactions with the TCR. MHC 
class I molecules are found on essentially all nucleated cells in the body allowing 
CD8+ T cells to recognize many different infected cell types. Following stimulation 
by antigen, T cells can be activated by co-stimulation via CD4+ Th cell-dependent or 
Th–independent mechanisms, such as self-help (268), to become CTLs. CTLs can 
then recognize target cells using their TCR and kill via granule-mediated cytolysis or 
Fas-Fas ligand (FasL) stimulation of apoptosis. Once activated, T cells undergo 
clonal expansion with the help of IL-2, a driver of the cellular immune response. 
Some CD8+ T cells can also differentiate into memory cells that persist after 




Production of pox-specific CTLs peaks 5-6 dpi and have been shown to be 
crucial in the specific defense against poxviruses (269). However, pox-specific CTLs  
are not essential for surviving VACV infection (196). Instead, it appears that CD4+ T 
cell-dependent antibody responses play the greatest role in clearance following acute 
infection. However, CD8+ T cells may play a more important role in the absence of 
an antibody response (251). When humans are vaccinated with VACV they develop 
poxvirus-specific CTL responses and both CD4+ and CD8+ T cell specific memory is 
maintained as memory cells (269). 
CD8+ T cells are stimulated by viral peptides loaded onto MHC class I 
molecules and can become effector CTL cells capable of direct cytolytic killing. 
CD8+ T cell responses in resistant B6 mice are very strong with as many as 60-80% 
of total CD8+ T cells being specific for ECTV at day 5 in the popliteal LN and day 7 
in the spleen (263, 270) Of these, up to 10% are specific to the immunodominant Kb 
epitope of ECTV158, the secreted IFN-γ binding protein (270, 271). When CD8+ T 
cells are depleted in C57BL/6 mice prior to footpad infection the animals become 
highly susceptible to mousepox, demonstrating the importance of CD8+ T cells for 
resistance (246). If the CD8+ T cell response is delayed, as it is in CD28-deficient 
C57BL/6 mice, animals have poorer control of virus spread and the disease becomes 
lethal in a higher proportion of mice (270). Thus, early and strong CD8+ T cells 
response are required for effective control of ECTV infection. These responses are 
independent of CD4+ T cell help or CD40-CD40L interactions (262, 263). In addition 
to their role in cytotoxicity, CD8+ T cells may play a role in protection against 




mousepox by Prf-mediated killing of infected cells within the draining LN, 
independent of IFN-gamma (272).  
 
2.4.17 B Cells and Antibodies 
The cellular response driven by CTLs is only one arm of the adaptive immune 
system. B cells, and the antibodies they produce, are the key components of the 
humoral response. Typically, these two competing immune responses work to 
complement each other. Factors such as pro-inflammatory cytokine IFN-γ stimulates 
T cells and the cellular arm, while anti-inflammatory IL-10 and IL-4 stimulate B cells 
and the humoral arm. There is evidence that B cells and antibody are required for 
viral clearance (249). 
As previously discussed, there are two infectious forms of VACV, the MV 
and EV. Each displays a unique population of proteins on their surface membranes 
requiring the immune response to generate responses to both forms. Antibodies are 
critical for protection against poxvirus infection in humans and primates (273), and as 
EVs are the major circulating form, it is not surprising that EV-targeting antibodies 
protect better against a lethal challenge in mice and rabbits than MV-targeting 
antibodies (274, 275). In humans the only neutralizing EV-specific antibodies are 
against the B5 protein, but anti-A27, L1, H3 and D8 antibodies against MV proteins 
have been observed (276, 277). Neutralization via anti-B5 antibodies appears to be 
facilitated by complement (278, 279). This suggests that the outer EV membrane acts 
as a shield to hide the highly antigenic MV membrane proteins during vulnerable 




MV proteins, may provide some protection by stimulating host humoral responses 
(281). 
As the protective properties of smallpox vaccination have been suggested to be due to 
antibody alone (282) the importance of antibodies in the protection against mousepox 
is of great interest. As previously described, when B cells or antibody production are 
inhibited, death is delayed suggesting that the role of antibody for clearance of ECTV 
is essential and occurs after the cytolytic response (266). The interaction of CD40 on 
B cells and CD154 on CD4+ T helper cells is essential for efficient antibody 
production. In C57BL/6 mice CD-40 deficient mice CTL responses are equivalent to 
wildtype C57BL/6 mice at 7 DPI, but antibody response are inefficient and death 
occurs 20-90 DPI. Adoptive transfer of CD40-sufficient B cells can restore resistance 
to mousepox (263). It is likely that cytotoxic CD8+ T cells serve as a first defense 
against the virus, but antibodies are essential in the prevention of death and clearance 
of the infection (163) 
Fenner demonstrated (103, 129, 283) that anti-HA antibody titers decline 
faster than immunity against mousepox, and that anti-VACV serum is only partially 
protective against mousepox. These findings suggest that antibody specificity may be 
complex and that it may not be the only correlate of protection. Anti-VACV 
antibodies, capable of recognizing ECTV MVs (as opposed to EVs), are capable of 
protecting or curing mousepox (284) which may provide one explanation for this 





2.4.18 Viral Pathogenesis 
The route of virus infection can be critical as it alters how the virus is introduced to 
the host and how the picture of disease being observed.  For example, peripheral 
routes of infection, specifically intradermal and subcutaneous, increase 
immunodominance following VACV infection (285, 286) versus the systemic 
infection following intranasal infection (287). Additionally, some VACV strains and 
isolates demonstrate reduced immunodominance of antigens and this correlates with 
reduced viral spread and robust priming, especially in the spleen (288).  
The removal or inactivation of the immunomodulatory proteins that have been 
discussed in this chapter often attenuate the infection. This can mean increased 
inflammation and immune cell infiltrates to the site of infection, and/or decreased 
viral titers at the site of infection and key organs. Sometimes this attenuation can vary 
between routes of infection. More information is needed to understand why these 
differences occur.  
One model that has been developed for the study of poxviruses in a natural 
host, and discussed in detail during this review, is mousepox. The potential of this 
animal infection model to help researchers break apart and understand the 
components of the immune response, viral immunomodulators that contribute to 
disease, and the mechanisms by which they do so, make it an ideal model for the 
characterization of poxviral diseases and viral virulence factors. Furthermore, the 
existence of genetically resistant and susceptible strains of mice has allowed 





2.4.19 Genetics of Resistance to Lethal Mousepox 
Mouse models have been used to demonstrate the importance of host genes in 
determining the severity to multiple viral infections and that this resistance is usually 
under polygenic determinants (289). As previously mentioned, delayed spread of 
ECTV to the spleen and liver in resistant C57BL/6 mice indicates a genetic role to the 
resistance of some mouse strains to mousepox. Two major components have been 
identified; T1-IFNs and NK cells. 
 In general, mouse strains resistant to lethal mousepox disease display a 
polarized type 1 cytokine response, and a potent cell-mediated immune response. A 
predominant type 2 response, or a lack of sufficient type 1 response, is characteristic 
of susceptible strains (131, 191). Genetic crosses have been useful in the search of the 
specific genetic components that dictate such responses. It appears that many of the 
genetic factors identified limit the early viral spread rather than viral replication 
within organs. 
 The resistant to mousepox 1 (rmp-1) gene on chromosome 6 was identified by 
crossing susceptible DBA/2 mice with resistant C57BL/6 mice and identifying a large 
locus, Prp, that confers a C57BL/6-like response to infection, thus indicating 
involvement in resistance to mousepox (244). The NK cell gene complex (NKC) 
(290) is adjacent to this locus and contains a variety of NK cell receptors (116, 118, 
233). The Klrd1 gene, encoding CD94, is not expressed by NK cells in susceptible 
DBA/2 mice. In NK cells, CD94 forms heterodimeric NK inhibitory receptors with 
NKG2A and activating receptors with NKG2C and NKG2E (291). The activating 




1b on ECTV-infected cells (292), thus providing a mechanism for the enhanced NK 
cell activity that promotes resistance in C57BL/6 mice. Interestingly, most Qa-1b-
deficient mice have increased early viral spread from the draining lymph node to the 
liver and spleen (163) demonstrating the importance of restricting early viral spread 
for survival. Interestingly, the CD94-NKG2A inhibitory receptor dimer has been 
demonstrated to optimize the CD8+ T cell response and is necessary for resistance to 
Ectromelia as it prevents over activation and exhaustion of T cells (293). 
 Additional genes have also been identified. Rmp-2 on chromosome 2 maps 
near the complement C5 gene and has been found to protect female mice better than 
male (294) Rmp-3 on chromosome 17 is also gender/gonad-dependent and has been 
linked to the MHC complex (294). It may even encode the Qa-1b gene identified as 
interacting with the presumptive rmp-1 gene, CD94 (163). Lastly, rmp-4 on 
chromosome 1 is found in an area with a variety of genes that could be involved in 
NK cell responses including; the genes for lymphotactin/XCL1, the NK and T-cell 






Chapter 3: Characterization of a large, 
proteolytically processed cowpox virus membrane 





Most poxvirus proteins are either highly conserved and essential for basic steps in 
replication or less conserved and involved in host interactions. Homologs of the 
CPXV219 protein, encoded by cowpox virus, are present in nearly all chordopoxvirus 
genera and some species have multiple copies. The CPXV219 homologs have 
estimated masses of greater than 200 kDa, making them the largest known poxvirus 
proteins. We showed that CPXV219 was expressed early in infection and cleaved into 
N- and C-terminal fragments that remained associated. The protein has a signal 
peptide and transited the secretory pathway where extensive glycosylation and 
proteolytic cleavage occurred. CPXV219 was located by immunofluorescence 
microscopy in association with the endoplasmic reticulum, Golgi apparatus and 
plasma membrane. In non-permeabilized cells, CPXV219 was accessible to external 
antibody and biotinylation. Mutants that did not express CPXV219 replicated 
normally in cell culture and retained virulence in a mouse respiratory infection model. 
                                                 
1 Adapted from: Reynolds, S. E. and Moss, B. Characterization of a large, 
proteolytically processed cowpox virus membrane glycoprotein conserved in most 







Poxviruses are large DNA viruses that reproduce in the cytoplasm of infected cells 
and have been widely studied because of their impact on human health, zoonotic 
spread, historic role as the first live virus vaccine, modern development as 
recombinant vaccine vectors, and use as model systems to investigate virus 
replication and host interactions (296, 297). Of the 200 or more proteins encoded by 
poxviruses, nearly 100 are conserved in all members of the chordopoxvirus subfamily 
and about half of those are also conserved in entomopoxviruses (44). The majority of 
the highly conserved proteins have essential roles in virus replication, whereas most 
of the less well conserved proteins of chordopoxviruses are concerned with 
modulating host interactions (298). The goal of the present study was to characterize 
an unusual protein that is widely conserved among the chordopoxvirus genera except 
for members of the parapoxvirus genus, suggesting an evolutionarily conserved but 
not strictly essential function. Curiously, vaccinia virus is the sole member of the 
orthopoxvirus genus that lacks an open reading frame (ORF) encoding this protein. 
With predicted molecular weights of more than 200 kDa, these conserved proteins are 
larger than any other known poxvirus proteins. Here we characterize the cowpox 
virus (CPXV) homolog encoded by open reading frame CPXV219 (UniProt 
Q8QMM9). CPXV is of particular interest because it may have been the original 
smallpox vaccine, is the cause of an increasing number of zoonoses, contains the 




orthopoxviruses (5, 25). CPXV219 was expressed early during infection, trafficked 
through the secretory pathway, was N-glycosylated and cleaved into two major 
fragments and exposed on the plasma membrane. Additional studies indicated that the 
CPXV219 gene was dispensable for growth in tissue culture and unnecessary for 
virulence in mice. 
 
3.2 Results 
3.2.1 CPXV219 is conserved in most chordopoxviruses  
The CPXV219 ORF of the Brighton red strain of CPXV is located near the right end 
of the genome and is predicted to encode a 1919 amino acid protein with a N-terminal 
signal peptide (SP), a near C-terminal transmembrane (TM) domain, two additional 
hydrophobic domains, and sites of N-linked glycosylation (Fig. 3.1A–C). With the 
exception of VACV, all sequenced orthopoxviruses have similar length homologs. In 
VACV strain WR, the absence of DNA adjacent to the expected site of the CPXV219 
homolog suggests the occurrence of a large deletion. The amino acid sequence 
identities of CPXV219 homologs of the orthopoxviruses ectromelia virus, variola 
virus, monkeypox virus and horsepox virus compared to CPXV are 93%, 93%, 85% 
and 86%. Except for parapoxviruses, at least one strain of all other chordopoxvirus 
genera encodes a CPXV219 homolog with sequence identity of 30–45% relative to 
CPXV219. The highest sequence conservation of CPXV219 homologs is in the C-
terminal region and some sheeppox strains have a N-terminal deletion. Avipoxvirus 
strains contain 5–6 duplicated full-length homologs in the center of the genome and 





Figure. 3.1 Predicted features of CPXV219 
(A) Diagram of CPXV219 ORF. Top shows the position of CPXV219 (blue) flanked 
by ORFs of unknown function (pink) near the right end of the CPXV genome. CPXV 
Serp123 corresponds to VACV C12L. Within the gene is a 20 amino acid N-terminal 
signal peptide (SP) predicted by the SignalP program 
(http://www.cbs.dtu.dk/services/SignalP/), a strongly predicted C-terminal 
transmembrane (TM) domain and hydrophobic domains (HD) that were more weakly 
predicted TMs by the DAS TM prediction server (http://www.sbc.su.se/ 
miklos/DAS/). (B) Hydrophobicity plot of CPXV219 predicted by the Protscale 
program using a window of 9 (http://web.expasy.org/cgi-bin/protscale/protscale.pl 





 been recognized in entomopoxviruses, non-poxvirus species or prokaryotic or 
eukaryotic organisms. 
 
3.2.2 CPXV219 is non-essential for replication  
The absence of a CPXV219 homolog in VACV suggested that the protein is not 
essential for replication and a recent study determined that CPXV219 could be 
deleted from CPXV, though the growth properties of the mutant were not described 
(299). To more fully analyze the requirement of the 219 protein for CPXV 
replication, homologous recombination was used to make a deletion mutant (CPXV 
219delGFP) by replacing the entire approximately 6000 bp ORF in CPXV with one 
encoding the green fluorescent protein regulated by a VACV promoter in the same 
orientation as CPXV219. Recombinant virus plaques were identified by fluorescence 
microscopy and clonally purified by repeated plaque isolation. In addition, the GFP of 
CPXV 219delGFP was replaced with the original CPXV219 gene in order to make 
the control virus CPXV 219Rev and with one containing stop codons near the N-
terminus to make the mutant CPXV 219Stop. PCR and DNA sequencing confirmed 
the genomic modifications (data not shown). In addition, we confirmed that the stop 
codons arrested translation by constructing and testing a recombinant CPXV that had 
the same stop codons in the CPXV219 gene with a C-terminal epitope tag (shown in 
Fig. 3.3D). The CPXV 219delGFP and CPXV 219Stop viruses replicated under one 
step growth conditions and formed plaques as well as the parent and CPXV 219Rev 
control viruses in BS-C-1 cells (Fig. 3.2A, B) or HeLa, RK13, BHK21 and MRC5 






Figure 3.2 CPXV219 is not essential for virus replication 
(A) One step growth curve. HeLa cells were infected with 3 PFU/cell of the parent 
CPXV strain Brighton (CPXBR) and CPXV 219delGFP, 219Rev and 219Stop and 
the cells plus media were collected at the indicated times. The cells were lysed by 
repeated freeze-thawing and the virus titers were determined by plaque assay on BS-
C-1 cells. (B) Plaque formation. BS-C-1 cells were infected with the indicted viruses, 





Figure 3.3 Expression of CPXV219 
(A) Diagram of the CPXV219 protein containing a V5 epitope tag immediately after 
the predicted SP and an HA epitope tag just before the termination codon expressed 
by CPXV V5-219-HA. The arrow indicates the predicted cleavage site. (B) Western 
blots. HeLa cells were infected with 3 PFU per cell and whole cell lysates were 
collected at the indicated hours. In parallel, cells were pretreated and infected with 5 
mg/ml (1X) or 50 mg/ml (10X) of BFA or 40 mg/ml AraC for 24 h. The infected cells 
were lysed with β-mercaptoethanol and SDS and the proteins were resolved by SDS-
PAGE. The proteins were transferred to a membrane, probed with antibodies to the 
V5 (green) and HA (red) epitopes and visualized by infrared fluorescent imaging. 
Yellow indicates coincidence of V5 and HA antibodies. (C) Association of N- and C-
terminal fragments. HeLa cells were infected with 5 PFU per cell of CPXV V5-219-
HA for 24 h, harvested in non-denaturing lysis buffer, and incubated with anti-V5 or 




bound to magnetic protein G Dynabeads and then analyzed by SDS-PAGE and 
Western blotting. (D) Absence of internal initiation. BS-C-1 cells were infected with 
5 PFU per cell of CPXV 219RevHA, CPXV 219Stop-HA and CPXV M1mut-HA. 
After 24 h, whole cell lysates were analyzed by SDS-PAGE and Western blotting 
using antibody to the HA epitope tag, and visualized by infrared fluorescence. The 




CPXV replication in cell culture. 
 
3.2.3 CPXV219 is expressed early in infection as full-length and N- and C- 
terminal fragments  
Initial Western blotting experiments employing a recombinant CPXV with a FLAG 
tag at the C-terminus of CPXV219 revealed a minor band with an apparent mass 
greater than the 260 kDa marker, a major band of about 160 kDa and additional more 
rapidly migrating products (data not shown). To further investigate synthesis and 
apparent processing of CPXV219, we constructed a recombinant CPXV containing 
specific epitope tags at both the N- and C-termini. Because of the large size of the 
ORF, a stepwise green-to-white and white-to-green fluorescence screen was used to 
first replace the C-terminus with GFP and then replace the GFP with the C-terminus 
of CPXV219 containing an HA tag just before the termination codon to form CPXV 
219-HA. A similar two-step procedure was used to replace the N-terminus of 219-HA 
with GFP and then with the N-terminus of CPXV219 containing a V5 tag 
downstream of the predicted SP to form CPXV V5-219-HA. In this manner, we 
obtained a recombinant virus with a specific tag at each end of CPXV219 (Fig. 3.3A). 
The addition of the epitope tags did not affect plaque formation or growth kinetics 
(not shown). To analyze protein synthesis, HeLa cells were infected with CPXV V5-
219-HA, collected at sequential times and lysed directly in buffer containing SDS and 
β-mercaptoethanol. The proteins were resolved by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to nitrocellulose filters and probed with 




to be visualized in the same gel. The major CPXV219 bands were prominent at 4 h, 
increased at 6 h and unchanged at 8 h suggesting an early promoter (Fig. 3.3B), 
which was consistent with the putative promoter sequence preceding the ORF (not 
shown). Expression of CPXV219 in the presence of cytosine arabinoside (AraC), an 
inhibitor of DNA replication that prevents intermediate and late gene expression, 
confirmed regulation by an early promoter (Fig. 3.3B). Antibodies to both N- and C-
terminal tags recognized the slowest migrating band with an estimated mass of 260 
kDa (which appeared yellow due to the overlap of red and green), indicating that it 
was the full-length protein. This protein was present in increased amounts, relative to 
the smaller ones, at 24 h. Antibody to the N-terminal tag recognized a 110-kDa band 
in addition to the full-length protein, whereas antibody to the C-terminal tag 
recognized a prominent 160-kDa band as well as smaller bands ranging from 80 to 40 
kDa in mass (Fig. 3.3B). 
 
3.2.4 Association of the N- and C-terminal fragments of CPXV219  
Western blotting indicated that most of the CPXV219 is present as N- and C-terminal 
fragments. Although the fragments separated under denaturing and reducing 
conditions, there was a possibility that they remain associated in infected cells. To 
investigate whether the fragments associate with each other, we carried out 
immunoprecipitation (IP) experiments. HeLa cells were infected with the CPXV V5-
219-HA and solubilized with 1% NP-40. The lysates were incubated with antibody to 
the V5 or HA tags in the presence or absence of 0.4% SDS to allow separation of 




washing, the proteins were eluted from the beads and analyzed by SDS-PAGE and 
Western blotting (Fig. 3.3C). When anti-V5 MAb was used to capture the CPXV219 
protein, irrespective of SDS, the N-terminal V5 and C-terminal HA fragments were 
detected by Western blotting indicating their association. Similarly, when anti-HA 
MAb was used to capture the CPXV219 protein, both fragments were detected by 
Western blotting. Control experiments showed absence of pulldown with irrelevant 
anti-FLAG MAb. Intracellular co-localization shown below by confocal microscopy 
also supported the association of the N- and C-terminal fragments. 
 
3.2.5 Proteolytic processing of CPXV219  
We considered several possibilities for the appearance of multiple forms of 
CPXV219: proteolytic cleavage, internal transcription initiation and internal 
translation initiation. Additional CPXV mutants were constructed to rule out a 
possibility that the 160-kDa and smaller C-terminal fragments arise from internal 
transcription or translation start sites. Starting with the virus containing CPXV219 
that had GFP replacing the N-terminus and HA at the C-terminus (used for making 
CPXV V5-219-HA), we swapped GFP with either (i) the N-terminus of CPXV219 in 
which the first methionine was mutated from ATG to AGT (CPXV 219M1mut-HA) 
or (ii) in which the codons at position 5 and 10 were mutated to stop sequences 
(CPXV 219Stop-HA) or (iii) the original N-terminus was restored (CPXV 219Rev-
HA). The recombinant viruses with HA-tags at the C-termini were clonally purified 
and characterized by PCR and DNA sequencing of the relevant portion of the 




analyzed by SDS-PAGE and Western blotting with antibody to the C-terminal HA tag 
(Fig. 3.3D). No C-terminally labeled bands were detected from cells infected with 
CPXV 219StopHA or CPXV 219-M1mut providing evidence against internal 
initiation and supporting the model in which CPXV219 is produced as a long 
polypeptide and subsequently cleaved. Cleavage of CPXV219 could be carried out by 
viral or cellular proteinases. The two predicted viral proteinases are homologs of 
VACV I7 (71, 300) and G1 (301, 302), which are expressed post-replicatively. 
Although not characterized in CPXV, the putative promoter sequences suggested that 
they are also expressed post-replicatively. Since cleavage of CPXV219 occurred in 
the presence of a DNA replication inhibitor (Fig. 3.3B), it seemed unlikely that either 
the I7 or G1 homologs were involved. In view of the predicted signal peptide and C-
terminal TM domain, we considered that proteinase cleavage might occur by a 
cellular enzyme during transit through the secretory system. The drug brefeldin A 
(BFA) inhibits protein transport from the endoplasmic reticulum to the Golgi 
apparatus indirectly by preventing formation of COPI mediated transport vesicles 
(303, 304). When CPXV V5-219-HA infected cells were treated with BFA, there was 
an accumulation of the 260-kDa band and reductions of the smaller 160- and 110-kDa 
bands, suggesting that cleavage occurs in the Golgi or a post-Golgi compartment 
during transport of CPXV219 through the secretory pathway (Fig. 3.3B). 
 
3.2.6 CPXV219 undergoes SP cleavage  
In a prior construct, we placed the V5 tag after the putative SP to ensure that it would 





Figure 3.4 Signal peptide cleavage and glycosylation of CPXV219 
(A) Western blots. HeLa cells were infected with 10 PFU per cell of viruses 
expressing CPXV219 proteins that contain a single FLAG epitope tag following the 
putative CPXV219 SP (SP-219), the VSV-G SP (VG-SP) replacing the CPXV 219 
SP, or non-cleavable VSV G SP (VG*-SP) replacing the CPX V219 SP. After 18 h, 
whole cell lysates were treated with β- mercaptoethanol and SDS and analyzed by 
SDS-PAGE and Western blotting. Separate membranes were blotted with anti-FLAG 
clone M2 or anti-FLAG antibody clone M1 and visualized by infrared fluorescence 




with 3 PFU per cell of CPXV V5-219-HA or parental CPXV-BR. After 18 h, the cells 
were harvested, lysed with 50 mM Tris pH 7.0, 150 mM NaCl, and 0.5% NP-40 
detergent and nuclei removed by centrifugation. The clarified lysates were incubated 
with PNGaseF, EndoH, or left untreated and analyzed by SDS-PAGE and Western 
blotting. Antibodies to V5 (green) and HA (red) were visualized by infrared 
fluorescence. Yellow result from coincidence of red and green. The positions of 




followed a previously described strategy (305) that takes advantage of two MAbs that 
react with the 19 amino acid FLAG tag: one (M1) reacts with the FLAG epitope only 
when it is located N-terminally, whereas the other (M2) reacts with internal as well as 
N-terminal FLAG epitope. Thus, reactivity with M1 MAb could occur only after SP 
cleavage. Three recombinant viruses were constructed with FLAG tags at the N-
terminus (Fig. 3.4A). One construct (CPXV SP-FLAG-219) contained the predicted 
SP sequence of CPXV219 immediately preceding the FLAG epitope tag; a positive 
control (CPXV VGSP-FLAG-219) was created by replacing the predicted CPXV219 
SP sequence with the known SP sequence of the G protein of vesicular stomatitis 
virus (VSV) followed by the FLAG epitope tag; a negative control (CPXV VG-SP*-
FLAG-219) was generated using a VSV-G SP sequence with two amino acids 
mutated that impair cleavage (306). Cells were infected with the three viruses and the 
lysates were analyzed by SDS-PAGE and Western blotting. Using the M2 antibody, 
we showed that the three proteins were expressed and contained the FLAG epitope 
(Fig. 3.4A). However, only the SP-FLAG- 219 and VGSP-FLAG-219 were detected 
by the M1 MAb that is specific for N-terminal FLAG, which could only arise by SP 
cleavage at the ER (Fig. 3.4A). The negative control VG-SP*-FLAG-219 was not 
detected with M1 MAb (Fig. 3.4A). These results confirmed the prediction of signal 
peptide cleavage at the N-terminus of CPXV219.  
 
3.2.7 CPXV219 is N-glycosylated in the ER and traffics to the Golgi apparatus  
The finding of SP cleavage as well as the effect of BFA on cleavage of CPXV219 




account for apparent mass of 4260 kDa determined by SDS-PAGE, whereas the ORF 
sequence predicts a mass of 215 kDa. Bioinformatics predicted numerous N-
glycosylation sites clustered mainly between codons 69 and 364 and additional sites 
between codons 997 and 1776 (Fig. 3.1A). To test these predictions, lysates of cells 
infected with CPXV V5-219-HA were digested with peptide N-glycosidase F 
(PNGaseF), which cleaves between the innermost GlcNAc and asparagine residues of 
N-linked glycoproteins and endoglycosidase H (EndoH), which also cleaves 
asparagine-linked oligosaccharides but not after further processing in the Golgi 
apparatus. Thus, EndoH-resistance can occur after transit to the Golgi apparatus. 
Undigested and digested proteins were analyzed by SDS-PAGE and Western blotting 
with antibodies to V5 and HA. As predicted, the N-terminal segment of CPXV219 
exhibited a large mobility shift, equivalent to 45-kDa, upon PNGase digestion 
whereas the C-terminal segment was reduced by only about 10-kDa (Fig. 3.4B). The 
combined mass of the PNGase-digested N- and C-terminal fragments was similar to 
that predicted for the full-length CPXV219, indicating that there is one or a few 
closely spaced cleavage sites at about 600 amino acids from the start codon. Mobility 
shifts of full-length, N-terminal and C-terminal fragments also occurred after EndoH 
digestion (Fig. 3.4B). However, EndoH digestion did not decrease the mobility of the 
N-terminal fragment as much as PNGase suggesting partial resistance due to 
carbohydrate processing in the Golgi apparatus.  
 
3.2.8 Cellular localization of CPXV219  




localize V5-CPXV219-HA and its cleavage products by confocal microscopy. 
Extensive co-localization of the probes within the cell and at the plasma membrane 
supported the association of the N- and C-terminal fragments (Fig. 3.5A). Another 
recombinant CPXV with C-terminal triple-FLAG (219-3xFLAG), which allowed 
sensitive detection with anti-FLAG M2 MAb, was used for intracellular localization. 
Polyclonal antibodies to cell proteins were also used for co-localization. Cells in 
which CPXV219 co-localized with cellular calnexin, ERGIC-53 and GM130 
targeting the ER, ER-Golgi intermediate compartment and cis-Golgi apparatus, 
respectively, are shown in Fig. 3.5B. The plasma membrane also appeared to be 
stained with FLAG antibody (Fig. 3.5B). Taken together these results suggested that 
CPXV219 traverses the entire secretory pathway rather than halting in one 
compartment. Additional experiments were carried out to confirm the plasma 
membrane localization of the CPXV219 and determine whether the protein is 
accessible from outside the cell. In order to gain high sensitivity, the cells were 
infected with CPXV 219-3xFLAG virus (Fig. 3.4). Signal peptide cleavage and 
glycosylation of CPXV219. (A) Western blots. HeLa cells were infected with 10 PFU 
per cell of viruses expressing CPXV219 proteins that contain a single FLAG epitope 
tag following the putative CPXV219 SP (SP-219), the VSV-G SP (VG-SP) replacing 
the CPXV 219 SP, or non-cleavable VSV G SP (VG*-SP) replacing the CPX V219 
SP. After 18 h, whole cell lysates were treated with β- mercaptoethanol and SDS and 
analyzed by SDS-PAGE and Western blotting. Separate membranes were blotted 






Figure 3.5 Cellular localization of CPXV219 
(A) HeLa cells were infected with 5 PFU per cell of CPXV V5-219-HA for 8 h. The 




conjugated antibodies to the V5 and HA epitope tags. The cells were also stained with 
DAPI to visualize nuclei and virus factories (arrows). (B) HeLa cells were infected 
with 3 PFU per cell of CPXV 219-3XFLAG for 8 h and then fixed and permeabilized. 
Cells were stained with antibodies against the C-terminal FLAG of CPXV219 (red) 
and either calnexin (green), ERGIC 53/p53 (green) or GM130 (green), which localize 
in the ER, ERGIC and Golgi network, respectively. DNA in nuclei and virus factories 
are stained with DAPI (blue). Yellow represents the colocalization of green and red. 




 (upper) and chemiluminescence (lower). (B) Glycosylation. HeLa cells were infected 
with 3 PFU per cell of CPXV V5-219-HA or parental CPXV-BR. After 18 h, the cells 
were harvested, lysed with 50 mM Tris pH 7.0, 150 mM NaCl, and 0.5% NP-40 
detergent and nuclei removed by centrifugation. The clarified lysates were incubated 
with PNGaseF, EndoH, or left untreated and analyzed by SDS-PAGE and Western 
blotting. Antibodies to V5 (green) and HA (red) were visualized by infrared 
fluorescence. Yellow results from coincidence of red and green. The positions of 
marker proteins are shown on the left of each panel and stained with anti-FLAG M2 
antibody with and without Triton X-100 permeabilization. As a positive control, 
infected cells were stained with a MAb that binds to the VACV B5 homolog on the 
surface of unpermeabilized cells. Antibody to L1 a mostly intracellular virion 
component was used as a negative control. Staining of CPXV219-FLAG in 
unpermeabilized cells produced a distinct ring that delineated the outside of the cell 
with the same pattern as B5, but not seen with L1 (Fig. 3.6A). After permeabilization, 
CPXV219-FLAG, B5, and L1 were all stained. The extracellular staining of the C-
terminal tag of CPXV219-FLAG demonstrated that the 40 amino acids following the 
TM domain are extracellular. The relatively weak signal obtained with the N-terminal 
V5 tag precluded attempts to demonstrate extracellular localization of the N-terminal 
V5 tag (data not shown). To support the immunofluorescence data, we used a 
nonmembrane permeable biotin (NHS-SS-Biotin) to label extracellular proteins on 
live cells infected with CPXV V5-219-HA. Lysates were prepared and incubated with 
beads attached to NeutrAvidin to purify biotinylated proteins. After washing the 





Figure 3.6 Localization of CPXV219 on the cell surface 
(A) HeLa cells were infected with 3 PFU per cell of CPXV 219-3XFLAG and stained 
with FLAG M2 MAb (red) and polyclonal anti-B5 (green) or anti-L1 (green) 
antibody either prior to treatment (UnPerm) or following fixation in 4% 
paraformaldehyde and permeabilization with Triton X-100 (Perm). DNA was stained 
with DAPI (blue). (B,C) Infections were carried out for 18 h with 10 PFU/cell of 
viruses with epitope tags at the N- or C-termini and then incubated with (+) or 
without (-) a non-membrane permeable biotin (NHS-SS-Biotin), washed to remove 
excess biotin, and harvested. Lysates were incubated with neutravidin beads and the 
bound proteins were eluted and analyzed by SDS-PAGE and Western blotting with 





 fragment of the biotinylated protein was detected using anti-HA and the N-terminal 
fragment with anti-V5 (Fig. 3.6B), whereas the proteins were not detected in the 
control without biotinylation. These results demonstrate that the N- and C-terminal 
fragments of CPXV219 remain associated at the cell surface. 
 
3.2.9 CPXV219 does not contribute to virulence in mice  
Although CPXV mutants with total or partial deletion of CPXV219 replicated well in 
cell culture, we considered the possibility that the protein might be more important 
during animal infection. CPXV 219Stop, without epitope tags or reporter genes, and 
CPXV 219Rev were used to infect BALB/c mice via the intranasal (IN) route with 
doses of 104 –106 PFU. At the low dose of 104 PFU, there was minor weight loss and 
100% survival of mice infected with the mutant and revertant viruses (Fig. 3.7A, B). 
At 105 PFU, there was slightly greater weight loss and lower survival with the 
revertant virus compared to the mutant virus, whereas at 106 PFU the weight loss was 
similar for both and few mice survived (Fig. 3.7A, B). The calculated LD50 values of 
1.0 x 105 and 2.1 x 105 for CPXV 219Rev and CPXV 219Stop, respectively, 
suggested at most a minor effect of CPXV219 expression on virulence in BALB/c 
mice. We also compared the virulence of CPXV 219Stop and CPXV 219Rev in 
CAST/Eij mice, which are more susceptible to CPXV and other orthopoxvirus 
infections than BALB/c mice (307, 308). Because of their sensitivity to CPXV, the 
CAST/Eij mice were infected IN with CPXV 219Rev and CPXV 219Stop at 1, 10, or 






Figure 3.7 Comparison of CPXV 219rev and CPXV 219Stop in mouse infection 
models 
(A) Infection of BALB/c mice. CPXV 219rev and CPXV 219Stop were administered 
at doses of 104, 105 and 106 PFU intranasally to groups of 5 BALB/c mice and the 
animals were weighed daily. (B) Percent survival of BALB/c mice from panel A. (C) 
Survival of CAST/EiJ mice. CPXV 219Rev and CPXV 219Stop were administered at 
doses of 101, 102 and 103 PFU intranasally to groups of 5 CAST/EiJ mice and the 
animals were weighed daily. Percent survival was plotted. (D) Organ titers of mice 
from panel C. At time of death organs of CAST/EiJ mice were collected, weighed, 
and frozen. Organs were then homogenized and titered on BS-C-1 cells. The PFU/g 
was calculated for spleen, liver, lungs, and brain and the total PFU/organ for the 




survived. At 10 PFU, 60% of the mice infected with CPXV 219Rev survived and 
20% of those infected with CPXV 219Stop survived. At the high dose of 100 PFU, 
none of the mice infected with CPXV 219Rev survived, and 20% of those infected 
with CPXV 219Stop survived (Fig. 3.7C). Weight loss for all groups was minimal 
even up to death and none reached the 70% level that would trigger termination. 
LD50 values of 15 and 5 PFU were calculated for CPXV 219Rev and CPXV 
219Stop, respectively. Similar results were obtained in a second study (not shown). 
At the times of death, organs were harvested and titered by plaque assay on BS-C-1 
cells (Fig. 3.7D). The organs contained similar titers of CPXV 219Rev and CPXV 
219Stop and differences were not significant. We concluded that CPXV219 does not 
appear to contribute greatly to virulence during an IN infection of either BALB/c or 
more sensitive CAST/Eij mice. 
 
3.3 Discussion  
Our study of the CPXV219 protein was motivated by the very large size of the ORF 
and its conservation in most but not all chordopoxvirues. Indeed, members of some 
genera have multiple copies suggesting an important role. CPXV219 was synthesized 
within the first 4 h of infection and in the presence of an inhibitor of DNA replication, 
indicating an early stage promoter. By constructing a recombinant virus with epitope 
tags at both ends, we detected the full-length protein, which migrated with an 
apparent mass of > 260 kDa, and more abundant 110 kDa N-terminal and 160 kDa C-




Immunoprecipitation experiments, however, indicated that the fragments remained 
associated prior to denaturation in vitro. The possibility that the C-terminal fragment 
arose from internal initiation was ruled out by its failure to form either when stop 
codons were introduced near the N-terminus or by removing the start codon. An 
increase in amount of full-size protein occurred when BFA was added, suggesting 
that proteolytic cleavage occurred during transit through the Golgi apparatus. Further 
studies demonstrated cleavage of a signal peptide and transit through the secretory 
pathway. Extensive N-glycosylation, also occurred during trafficking; approximately 
45- and 10-kDa reductions in the masses of the N- and C-terminal fragments occurred 
following PNGase digestion. If we estimate that each N-glycosylation contributes 2.2 
kDa to protein mass, then approximately 20 of the 21 predicted sites in the N-terminal 
fragment were glycosylated and 4 or 5 of the 10 predicted sites in the C-terminus 
were glycosylated. The acquisition of endoH-resistance, particularly of the N-
terminal fragment, was further evidence of Golgi or post-Golgi transport. The 
CPXV219 protein was visualized throughout the secretory pathway including the 
plasma membrane and was detected in unpermeabilized cells by labeling with 
fluorescent antibody to a C-terminal epitope tag and confocal microscopy. Based on 
the available data, we suggest the topological model in Fig. 3.8. In step I, CPXV219 
is co-translationally inserted into the ER with cleavage of the signal peptide and 
glycosylation. In step II, the protein is transported to the Golgi network where 
modification of carbohydrate and proteolytic cleavage occur. In step III, the two 





Figure 3.8 Topological model of CPXV219 
I, the CPXV protein is co-translationally synthesized at the ER, with removal of the 
signal peptide, and glycosylated. II, the protein is transported to the Golgi network 
where the carbohydrate is modified and cleavage occurs to form two major 
fragments. III, the two fragments while still associated are transported to the plasma 
membrane where the segments that were in the ER are now extracellular. The linear 
model of CPXV219 shows placement of the signal peptide (SP), epitope tags (V5 and 
HA), cleavage site, N-glycosylated region, C-terminal transmembrane domain (TM) 




terminus was considered to be outside of the plasma membrane because the epitope 
tag was accessible to antibody in unpermeabilized cells. The site of CPXV219 
cleavage at approximately amino acid 600 of the full-length protein must have been 
in the ER based on the inhibition by BFA and at least part of the region between 
amino acid 1000 and 1800 must also have been in the ER since that is where the 
potential N-glycosylation sites are located. Assuming that the predicted TM near the 
C-terminus is utilized, then CPXV219 must traverse the membrane twice. There are 
two additional hydrophobic regions estimated between amino acids 925 to 938 and 
1317 to 1325, one of which must traverse the membrane. Based on the location of the 
potential N-glycosylation sites, we predict that the more distal hydrophobic site was 
used. This would mean that a loop between amino acids 1325 and 1856 is 
cytoplasmic. The entire N-terminal fragment must have been in the ER based on the 
cleaved signal peptide, the extent of N-glycosylation and the absence of additional 
hydrophobic domains. Since fluorescence microscopy showed the N-terminal 
fragment colocalizing with the C-terminal fragment within the cytoplasm and at the 
plasma membrane and co-immunoprecipitating with the C-terminal fragment, we also 
placed it on the cell surface in our model. However, further experimentation is needed 
to directly confirm the predicted topology. In a recent study Alzhanova et al. (308) 
analyzed the monkeypox virus (MPXV) homolog of CPXV219. Their study and ours 
were consistent in providing evidence for proteolytic cleavage of the full length 
protein and cell surface expression of the C-terminal fragment, despite 
methodological differences. In contrast to our approach, which involved construction 




Alzhanova et al. (309) relied on transient expression by plasmids in uninfected cells 
or by adenovirus vectors. Because the majority of their studies were carried out with 
only a C-terminal epitope tag, they did not demonstrate the formation of a stable N-
terminal fragment. The inhibition of cleavage by BFA suggested the action of a Golgi 
or post-Golgi proteinase. The approximately 65- and 150-kDa sizes of the 
deglycosylated CPXV219 fragments suggested that the major cleavage site or sites 
are about 600 amino acids from the N-terminus. The Arg-X-X-Arg and Arg-Arg 
sequences between amino acids 589 and 596 are candidate furin cleavage sites. A 
conserved run of Ser residues is just downstream of the putative cleavage sites and 
additional Ser residues are about 30 amino acids further downstream. A region rich in 
prolines (35%) and arginines (15%) with 14 PXXP sequences occurs between amino 
acids 706 and 778 of CPXV219 and is conserved in other orthopoxvirus homologs. 
Such proline-rich regions are found in SH3 domains and may be involved in protein–
protein interactions (310). Despite the conservation of CPXV219 homologs in most 
poxviruses, we found that introduction of stop codons near the N-terminus or deletion 
of the entire ORF had no effect on replication in tissue culture cells. This suggested 
that CPXV219 likely had a role in countering host defenses. However, the CPXV219 
null mutant was not attenuated in either BALB/c mice or the more sensitive CAST 
mice (308). We considered that other CPXV genes might make the role of CPXV219 
partially redundant or that the activity of CPXV219 is fine-tuned for its natural rodent 
host and is non-functional in mice. Both ideas are consistent with the recent report by 
Alzhanova et al. (309). While searching for a MPXV gene product that renders T-




macaque model, deletion of the MPX197 resulted in increased survival, reduced viral 
load, and increased levels of both CD4+ and CD8+ pox-specific T cells. The MPXV, 
VARV and CPXV homologs each inhibit human and monkey T cells but are less 
active on mouse T cells, providing a possible explanation for our finding that a 
CPXV219 null mutant did not affect the disease course of CPXV in mice. In addition, 
CPXV encodes two inhibitors of MHC class I presentation (241, 311, 312) that could 
compensate for the absence of CPXV219. In the future, we plan to investigate the role 
of the ectromelia homolog in the mouse, its natural host. 
 
3.4 Materials and Methods 
3.4.1 Cells  
BS-C-1 cells were propagated in minimum essential medium with Earle's salts 
supplemented with 10% fetal bovine serum, 100 U/mL of penicillin, and 100 mg/ml 
of streptomycin (Quality Biologicals, Gaithersburg, MD). HeLa cells were 
propagated in Dulbecco's modified Eagle's medium supplemented with 10% fetal 
bovine serum and antibiotics as described above.  
 
3.4.2 Recombinant CPXV219 viruses  
DNA sequences were generated using overlapping PCR for the purpose of 
homologous recombination in the generation of mutant viruses. The flanking regions 
of the C-terminus of CPXV219 were amplified from CPXV-BR genomic DNA using 
SR42 (5′ -AAG ATG CTA AAA ATA AGA AAA GGA CAT ATA-3′ ), SR96* (5′ -




ATT AGA ATC GTC ATG-3′ ), SR3n (5′ -ATG CAC GAG CTG TAC AAG TAA 
TAA TAA AAA AAT AGT TTA ACT CTT TTT AGA ACC AGT TTG-3′ ) and 
SR4 (5′ -GTT TAT ATC ACA GCA TTC TAC AAA CAG TCT AAA C-3′ ). In a 
second PCR the overlapping tails of the above primers (underlined) were used to 
flank GFP under the control of a VACV p11 promoter amplified using SR94 (5′ -TTT 
CAT TTT GTT TTT TTC TAT GCT ATA AAT GGT G-3′ ) and SR20 (5′ -TTA 
CTT GTA CAG CTC GTC CAT GCC GAG AGT GAT CCC-3′ ). The resulting PCR 
product containing an independently regulated GFP flanked by the regions up- and 
downstream of the 219 C-terminus was gel purified and transfected (lipofectamine 
2000, Invitrogen) into cells infected with CPXV-BR. Recombinant viruses that 
express GFP were detected by fluorescence microscopy and isolated by three rounds 
of plaque purification beneath a 5% methylcellulose overlay. The correct site and 
sequence of the CPXV219-CtdelGFP recombinant was confirmed by PCR.  
C-terminally tagged CPXV219 was generated using the same homologous 
recombination method described above but replacing GFP with the wild-type C-
terminal CPXV219 sequence and an HA tag (N-YPYDVPDYA-C) immediately prior 
to the stop codon. The primers SR105 (5′ -AGC GTA GTC TGG GAC GTC GTA 
TGG GTA GTA CCG ATT ATC CAT AAT TTC CAT AGA TAC TG-3′ ) and 
SR106 (5′ -CGA CGT CCC AGA CTA CGC TTA ATA AAA AAA TAG TTT AAC 
TCT TTT TAG AAC CAG TTT GG-3′ ) were used in overlapping PCR to generate 
the recombination fragment. Non-fluorescent plaques were purified in tissue culture 
and generation of CPXV 219-CtHA was confirmed by PCR and sequencing.  




GKPIPNPLLGLDST-C) of the doubly tagged mutants of CPXV219. The primers 
SR1 (5′ -AAC ATG AGT ATT CTA GGT GTC TCT ATT GAA TG-3′ ), SR93 (5′ -
CAC CAT TTA TAG CAT AGA AAA AAA CAA AAT GAA AGG TTG CCG 
GTC ATA AAC AAA CC-3′ ), SR95 (5′ -CAT GCA CGA GCT GTA CAA GTA 
ATA TAA TTG TAA ACT AAC TAC AAA TTC TGC ATG TGA TG-3′ ) and 
SR55 (5′ -GCA TAA GTT ACC TCT TTA ACA CTA GAA AGC TTT TGG-3′ ) 
were used, along with the previously described GFP amplification, to create the GFP 
deletion construct CPXV219-NtdelGFP. Primers SR138 (5′ -GGT CGA GTC GAG 
GCC GAG GAG GGG GTT GGG GAT GGG CTT GCC ACA CCA CGA ACA 
TGT CGC-3′ ) and SR139 (5′ -CGG CCT CGA CTC GAC CTA TGA AAC ATG 
TGT AAG AAA ATC TGC ATT G-3′ ) were used to generate the N-terminal 
recombination product in which the V5 tag was inserted directly following the signal 
peptide cleavage site. Plaques were purified and confirmed by PCR and sequencing. 
Mutants used to confirm the signal peptide were similarly generated from the CPXV 
219-NtdelGFP in which a single FLAG tag (N-DYKDDDDK-C) was inserted 
immediately following the wild-type CPXV219 signal peptide (N-
MNLQRLSLAIYLTATCSWC-C), a known signal peptide (SP) sequence from the 
VSV-G protein (VG-SP: N-MKCLLYLAFLFIGVNC-C), or the known SP with a 
single mutation (bold) disrupting cleavage (VG-SP*: N-MKCLLYLAFLFIGVNR-C) 
as shown in Husain et al. (305).  
Viruses were propagated in BS-C-1 cells and released through 3 repeated 
freeze/thaw cycles. Samples were sonicated prior to each use and viral titers were 





3.4.3 Antibodies  
The HA epitope tag was detected with anti-HA clone HA-7 Mab (Sigma), anti-HA 
rabbit Pab (Invitrogen) or horseradish peroxidase (HRP)-conjugated rabbit anti-HA 
polyclonal antibody (PAb) (Thermo). The V5 epitope tag was detected with anti-V5 
SV5- Pk1 MAb (Thermo) or with HRP conjugated anti-V5 rabbit PAb (Bethyl). 
Directly conjugated anti-HA mouse IgG1, clone 16B12 (Life Technologies) and anti-
V5 FITC clone SV5-Pk1 (Thermo) were used for confocal microscopy. The FLAG 
epitope tag was detected with either anti-FLAG M2 MAb or anti-FLAG M1 MAb 
(Sigma) specific for FLAG at the free N-terminus. Anti-calnexin, anti-ERGIC- 
53/p53 and GM130 (C-terminal) rabbit PAbs were obtained from Sigma. The anti-B5 
rat MAb 19C2 (82) and anti-L1 rabbit PAb (313) were described previously.  
 
3.4.4 Western blotting  
Cells were harvested and lysed in 2 x SDS sample buffer added directly to the cell 
monolayer. Cell lysates were disrupted in a cup sonicator and heated to 95 °C for 10 
min. Equal volumes of lysates were analyzed by SDS-PAGE using a 4–12% Tris–
glycine gel and 1 x Tris–glycine SDS running buffer (Invitrogen) at 125V for 2 h. 
Samples were transferred via a semi-dry transfer (Invitrogen) and nitrocellulose 
membranes were blocked in 5% milk in Tris-buffered saline with 0.1% Tween-20. 
Antibodies were incubated at a 1:1000 dilution in 5% milk overnight. Proteins used 
for Western blots were detected using anti-mouse and/or anti-rabbit secondary 




infrared imager (LI-COR Biosciences, Lincoln, NE). For visualization of the anti-
FLAG M1 antibody, goat anti-mouse HRP secondary (KCL, diluted 1:10,000) was 
visualized using chemiluminescence (ECL, Thermo).  
 
3.4.5 Glycosidase treatment of cell lysate  
HeLa cells (2.5 x 105) were washed in phosphate-buffered saline (PBS) and lysed in 
75 ml of 50 mM Tris pH 7.0, 150 mM NaCl, and 0.5% NP-40 detergent on ice for 20 
min. Nuclei were removed by low-speed centrifugation (400 x g, 5 min, 4 °C). The 
supernatants were adjusted to contain 0.5% SDS and 1% β-mercaptoethanol and 
heated at 95 °C for 10 min. PNGaseF (1500 U) or EndoH (1500 U; New England 
Biolabs) was added and incubated overnight at 37 °C. Samples were analyzed by 
SDS-PAGE and Western blotting.  
 
3.4.6 Confocal microscopy  
HeLa cells were grown on coverslips (12 Circle #1, Thermo) to approximately 80% 
confluency in 24-well plates and infected with CPXV219 mutants at multiplicity of 3 
PFU/cell for the indicated amount of time at 37 °C. Cells were washed briefly in PBS 
and fixed in 4% paraformaldehyde in PBS. Cells were permeabilized in 0.1% Triton 
X-100 for 10 min and blocked in 10% fetal bovine serum in PBS for at least 1 h at 
room temperature. Antibody was incubated overnight at a 1:250 dilution in blocking 
buffer at 4 °C, washed in PBS, and incubated with secondary (Life Technologies, 
Alexa-fluor mouse-488, rabbit-594) at a 1:250 dilution in blocking buffer for 4–18 h. 




(DAPI, Invitrogen) 1:1000 in H2O for 30 min, washed in PBS, mounted to glass 
slides with a drop of prolong gold anti-fade mounting media (Invitrogen) and viewed 
with a confocal microscope.  
 
3.4.7 IP analysis  
HeLa cells were infected at a multiplicity of 5 PFU per cell for 24 h and harvested in 
lysis buffer containing 1% NP-40, 50 mM Tris– HCl, 150 mM NaCl, 100 ml EDTA 
and complete protease inhibitor (Roche) and allowed to proceed at 4 °C for 30 min. 
The lysates were cleared by centrifugation at 1600 rpm for 15 min at 4 °C. IP was 
carried out overnight using 2–4 mg of either anti-V5 or anti-HA MAb in the presence 
or absence of 0.4% SDS using 15–25 ml of magnetic protein G Dynabeads 
(Invitrogen). After incubation, the beads were washed in PBS containing 0.5% 
Tween-20 and resuspended in 2x SDS sample buffer (0.125 M Tris–HCl, pH 6.8, 4% 
SDS, 0.005% Bromophenol Blue, and 20% glycerol) with 5% β-mercaptoethanol 
(Sigma), heated to 95 °C for 10 min, and analyzed by Tris–glycine SDS-PAGE.  
 
3.4.8 Biotinylation of extracellular proteins  
HeLa cells were infected with epitope-tagged CPXV at a multiplicity of 10 PFU per 
cell for 18 h, washed in PBS, labeled with 0.5 mg/ ml of a non-membrane permeable 
biotin (NHS-SS-Biotin, Thermo), washed to remove excess biotin, quenched by 10 
min wash in 2.5% fetal bovine serum in EMEM, and incubated in lysis buffer 
containing 10 mM Tris–HCl, 10 mM NaCl, 5 mM MgCl, 1% Triton X-100, 0.5% 




with 15–25 ml of Neutravidin agarose beads (Thermo) and washed. The beads were 
treated with 2 x SDS sample buffer with 5% β-mercaptoethanol (Sigma), heated to 95 
°C for 10 min, and analyzed by Tris–glycine SDS-PAGE and Western blotting.  
 
3.4.9 Intranasal infection model  
All experimental procedures involving mice were approved by the National Institutes 
of Allergy and Infectious Disease Animal Care and Use Committee and carried out in 
a humane manner. Female BALB/c and CAST/EiJ mice were purchased from 
Taconic Biosciences and Jackson Laboratory, respectively. Animals were kept in a 
clean environment in sterile microisolator cages. Groups of 5 BALB/c or CAST/Eij 
mice were anesthetized with isofluorane and inoculated in a single nostril with a 10 
ml suspension of sucrose-cushion purified virus. The infection inoculum was titered 
by plaque assay to confirm dosages. Mice were weighed daily following infection and 
euthanized if reached 70% of their initial body weight in accordance with NIAID 
Animal Care and Use protocols. All experiments were performed in an animal 









Chapter 4: A homolog of the variola virus B22 
membrane protein contributes to ectromelia virus 





Most poxviruses encode one or more homologs of a 200,000-kDa membrane protein 
originally identified in variola virus. We investigated the importance of the ectromelia 
virus (ECTV) homolog C15 in a natural infection model. In cultured mouse cells, the 
replication of a mutant virus with stop codons near the N-terminus (ECTV-C15Stop) 
was indistinguishable from a control virus (ECTV-C15Rev). However, for all doses 
injected into the footpads of BALB/c mice, there was less mortality with the mutant. 
At 1,000 PFU all mice survived ECTV-C15Stop infection, whereas none survived 
ECTV-C15Rev. Similar virus loads were present at the site of infection with mutant 
or control virus whereas there was less ECTV-C15Stop in popliteal and inguinal 
lymph nodes, spleen and liver indicating decreased virus spread and replication. 
Decreased spread was evidently not due to an intrinsic viral function of C15 as the 
survival of infected mice was dependent on host CD4+ and CD8+ T cells. 
 
                                                 
2 Adapted in part from: Reynolds, S. E., Earl, P.L., Moore, I., Moss, B. A homolog of the variola 
virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model. 





Poxviruses are large double-stranded DNA viruses that infect a wide variety 
of hosts. Within the chordopoxvirus subfamily are two obligate human pathogens 
(296): molluscom contagiosum virus, which causes a localized skin disease in young 
children and more extensive lesions in immunodeficient individuals, and variola virus 
(VARV), the causative agent of smallpox and member of the genus orthopoxviridae 
(OPXV). Other OPXVs can infect humans including the smallpox vaccine vaccinia 
virus (VACV), cowpox virus (CPXV), and monkeypox virus (MPXV). Host range 
can be broad as in the case of CPXV, which infects voles, mice, cats, elephants and 
humans, to the very limited ranges of VARV, camelpox virus and ectromelia virus 
(ECTV), an OPXV that infects only mice (16, 296).  
ECTV, the causative agent of mousepox, is unique among OPXVs because it is the 
only virus extensively studied in a natural host: the laboratory mouse (102, 131, 283). 
Mousepox has emerged as a valuable model for the study of OPXV pathogenicity as 
it causes a well-characterized smallpox-like disease (108, 109). Mouse genetic 
components that influence the immune response and susceptibility to mousepox have 
been identified and an early and strong type 1 immune response is key for survival 
(131, 191).   
Poxvirus genomes are organized with conserved, essential genes located 
centrally while more variable genes, often involved in host range determination and 
virus-host interactions, are located near the ends (297). Many of these viral immune 




information about their roles (145); however, the matched ECTV/mouse model 
provides the opportunity to study these proteins in the context of a natural infection. 
One putative immune modulator is the VARV B22 protein and its homologs found in 
representatives of most poxviruses (the one exception being parapoxviruses) and all 
OPXV except VACV. The presence of homologs in salmon gill poxvirus, the deepest 
member of the chordopoxvirus subfamily indicates that the gene was acquired early 
in poxvirus evolution (12). The presence of multiple copies in some poxviruses and 
extensive sequence divergence between genera are consistent with a long 
evolutionary history and host adaptation. The B22 family is also notable for 
comprising the largest size poxvirus proteins. The gene encoding the CPXV homolog 
of the B22 protein (CPXV219) is located near the right end of the genome and 
encodes a protein of 1,919 amino acids. The protein is expressed early in infection, 
has a signal peptide and transits the secretory pathway where extensive glycosylation 
and proteolytic cleavage occur prior to insertion into the plasma membrane (314). 
The MPXV homolog (MPXV197) has similar properties (309). The roles of CPX219 
and MPXV197 have been studied in mice and rhesus macaques, respectively. In 
mice, the absence of CPXV219 does not influence CPXV pathogenesis even in those 
that are more susceptible to OPXV infections than standard inbred laboratory strains 
(314). Although MPXV primarily infects African rodents, the absence of MPXV197 
results in a milder disease with accelerated T cell responses and less T cell 
dysregulation than in wildtype MPXV infection of rhesus macaques (309). When 
examined ex vivo B22 homologs show a species-specific ability to inhibit T cell 




human but not mouse T cells (309); the latter is consistent with our finding that 
deletion of the gene does not affect CPXV virulence in mice (314).  
The species-specificity of B22 homologs makes the mousepox model 
attractive for examining their role during poxviral disease in a natural host. C15, the 
ECTV homolog of B22 has an amino acid identity of 92, 91 and 83% with the 
corresponding CPXV, VARV and MPXV proteins, respectively. An ECTV mutant 
that does not express the C15 open reading frame was constructed and found to 
reduce mortality in mice susceptible to mousepox. At high doses of the C15 deletion 
mutant, the viral load in critical organs including the liver and spleen were reduced 
compared to wild type virus. Depletion studies showed that T cells were critically 
important for resistance of mice to the C15 mutant. The different effects in mice of 
deletion of B22 homologs from CPXV and ECTV highlight the importance of 




4.3.1 Construction and replication of ECTV C15 mutants 
To facilitate the generation of C15 mutant viruses, we first used homologous 
recombination to replace the DNA encoding the N-terminal region of C15 in ECTV 
strain Moscow with the open reading frame for enhanced green fluorescent protein 
(GFP). The recombinant virus was isolated from plaques exhibiting green 
fluorescence and then used in a second round of recombination in which GFP was 




control or C15 DNA with two stop codons near the N terminus to produce C15Stop 
virus. Plaques containing recombinant viruses were identified by absence of green 
fluorescence, clonally purified and verified by PCR and DNA sequencing. Stop 
codons in the same position were previously shown to prevent expression of CPX219 
(314). When sucrose cushion purified virus stocks were analyzed for particle to 
plaque forming unit (PFU) ratio with the virus counter (ViroCyt) or for genome to 
PFU ratio by droplet digital PCR there was no difference between mutant and 
revertant viruses (data not shown).   
To assess the impact of the C15 mutation on virus replication in tissue culture, 
mouse L929 cells were infected at a multiplicity of 3 PFU per cell. Samples were 
collected at various times post infection and virus titers determined by plaque assay 
on BS-C-1 cells. There were no observed differences in the rates or yields of virus 
replication in mouse L929 cells (Fig. 4.1) or of the plaque sizes on monkey BS-C-1 
cells (data not shown). 
 
4.3.2 Mortality following footpad infection of BALB/c mice 
Footpad inoculation causes severe disease in susceptible mice and is considered to be 
the route of ECTV infection that most closely mimics natural spread (121). To 
determine whether C15 expression influences the pathogenicity of ECTV, we 





Figure 4.1 C15 expression was not required for replication of ECTV in tissue culture 
Mouse L929 cells were infected with 3 PFU per cell of ECTV-Mos, C15Rev or 
C15Stop. Cells and growth media were harvested at various times post infection and 
virus titers were determined by plaque assays on BS-C-1 cells. Infections were done 







Figure 4.2 Absence of C15 reduces mortality after ECTV footpad infection 
Female 8-week old Balb/c mice were injected in the left hind footpad with 10 µl of 
C15Rev or C15Stop virus at doses of 10, 100 or 1,000 PFU per mouse. Shown are the 
combined results of two independent experiments each with five animals per dose. 
Endpoint was determined by natural death, or in 3 cases by the veterinarian’s 




from 10 to 1,000 PFU per mouse. Following footpad infection, death occurred 
primarily between days 9 and 12 with a few animals succumbing to the disease as late 
as day 18. No matter the viral dosage, infection with C15Stop resulted in less death 
than infection with C15Rev (Fig. 4.2). Paradoxically, mice died after 10 or 100 PFU 
of C15Stop but not 1,000 PFU. This result was consistent over multiple experiments 
and the absence of mortality was observed even at 20,000 PFU/mouse (data not 
shown). 
 Animals were scored based on their movement and the conditions of the coat, 
eyes and limb and the highest total scores at any time (Fig. 4.3A). Some animals died 
early with low scores while others survived longer and attained higher scores. The 
high scores of animals that were infected with 1,000 PFU/mouse of C15Stop virus 
and survived were similar to those of animals that were infected with C15Rev and 
succumbed.  
 Swelling of the infected foot occurred in most mice between days 5 and 7 and 
increased for several more days in surviving animals (Fig. 4.3B). On day 10, the 
swelling was significantly greater in the mice infected with C15Stop than with 
C15Rev. At later times, there were too few surviving animals infected with C15Rev 
for meaningful comparison.  
  
4.3.3 Decreased virus dissemination in mice infected with C15Stop 
To determine the basis for the greater mortality in mice infected with C15Rev than 
with C15Stop we examined organs known to be key in the spread and pathogenesis of 





Figure 4.3 Effect of virus dose on disease symptoms 
(A) Animals from Fig. 2 were scored for disease symptoms daily following infection. 
Movement and condition of the coat, eyes and limb all contributed to the score. The 
highest total score achieved at any time during disease course by each animal was 




and those euthanized in green. The bars represent the median and one standard 
deviation above and below. (B) For all animals in Fig. 2 footpad swelling was 
determined twice weekly by measuring the width and height of swelling and the size 
was calculated by multiplying these values. On day 13 only three C15Rev animals 
remained, and on day 18 only one C15Rev animal remained. All five C15Stop 
animals survived.  The bars represent the median values. On day 10 swelling was 




liver. Twenty animals were infected with 1,000 PFU of C15Rev or C15Stop and 5 
were sacrificed at each of 2, 4, 6 and 8 days post-infection. Organs were 
homogenized and virus titers determined. The titers in the foot increased from day 2 
to day 8 but were similar to each other in mice infected with C15Rev and C15Stop 
indicating that differences in mortality were not due to differences in replication at 
the site of infection (Fig. 4.4A). The popliteal lymph node was the closest organ to 
the site of infection that was analyzed. At day 2 only one C15Stop infected animal 
had a measurable virus titer in the popliteal node, whereas all mice infected with 
C15Rev had detectable titers. Furthermore, on days 6 and 8 the virus titers of 
C15Stop animals in the popliteal lymph node were less than C15Rev by 
approximately one log (p < 0.01, p < 0.05, respectively) (Fig. 4.4B). Infection of the 
inguinal lymph node was delayed compared to the popliteal but the pattern was 
similar: virus titers were detectable in two of five C15Rev infected animals on day 4 
but not in C15Stop animals, followed by less in the C15Stop animals on days 6 and 8 
(p < 0.01). Two animals infected with C15Stop still had no detectable virus in the 
inguinal lymph nodes on days 6 and 8, whereas C15Rev-infected animals had titers as 
high as 106 PFU/organ on day 8 (Fig 4.4C). 
 High virus loads in the spleen and liver are associated with death due to 
ECTV (115, 116). Following infection we detected virus in the spleen of C15Rev- 
and C15Stop-infected animals in similar amounts on day 4; however, on days 6 and 8 
there was less virus in the spleens of C15Stop-infected animals (p < 0.05, p < 0.01, 
respectively) (Fig. 4.4D). In the liver the difference between the virus titers of 






Figure 4.4 Absence of C15 reduces virus load 
Female 8-week old Balb/c mice were infected in the footpad with 1,000 PFU of 
C15Rev or C15Stop and organs were collected on days 2, 4, 6 and 8. Organs were 
homogenized and virus was titered on BS-C-1 cells. Foot, spleen and liver are shown 
as PFU/gram of tissue and lymph nodes as PFU/organ. Significant differences by 
Mann-Whitney are shown, p < 0.05 (*) or p < 0.01 (**). Plasma from infected 
animals was collected, DNA was purified and genome copy number was determined 
through the use of digital droplet PCR. Genomes are reported in copy number per µl 




(p < 0.01) (Fig 4.4E). The number of viral genomes in the plasma was determined by 
digital PCR. There was a trend for more viral genomes in animals infected with 
C15Rev than C15Stop (p = 0.095) (Fig 4.4F). The differences in virus loads in organs 
of animals infected with C15Stop and C15Rev indicated better control of the spread 
and/or replication of ECTV in the absence of the C15 protein. 
 The high virus dose of 1,000 PFU showed the greatest difference in mortality 
between C15Rev and C15Stop, but also an unusual phenomenon whereby animals 
infected with lower doses of C15Stop had greater mortality than with higher doses 
(Fig 4.2). To investigate this further we determined virus titers on day 8 from animals 
that received 10, 100 or 1,000 PFU. Although the virus titers from the foot increased 
significantly with virus dose, they were similar for mice infected with C15Rev and 
C15Stop (Fig 4.5A). In contrast, the titers in the inguinal and popliteal lymph nodes 
decreased with increasing dose of C15Stop but were similar or increased with 
C15Rev (Fig. 4.5B, C). A trend to lower virus loads with increasing dose of C15Stop 
also occurred in the liver although the titers in the spleen were more constant (Fig. 
4.5D, E). As in the lymph nodes, the amounts of virus in the spleens and livers of 
mice infected with C15Rev increased with dose (Fig. 4.5D, E). Overall, the results 
indicated that the decreased mortalities at high virus inocula were associated with 
decreased spread of C15Stop to the lymph nodes and internal organs.   
 
4.3.4 Histological analysis of organs 
Organs of mice infected with 1,000 PFU of C15Rev or C15Stop were examined 






Figure 4.5 Effect on inoculum size on virus load in organs 
Female 8-week old Balb/c mice were infected in the footpad with 10, 100 or 1,000 
PFU of C15Rev or C15Stop and organs were collected on day 8. Organs were 
homogenized and virus titered on BS-C-1 cells. Foot, spleen and liver are shown as 
PFU/gram of tissue. Lymph nodes are PFU/organ. Statistics were performed using the 











Figure 4.6 Histological analysis of organs 
Photomicrographs display images of haemotoxylin and eosin (H&E) staining on top 
rows and immunohistochemistry utilizing anti-VACV antibody that recognizes ECTV 
on bottom rows. The foot (A) and popliteal LN (B) are shown 4 DPI, and the inguinal 




C15Rev, C15Stop or uninfected (mock) were sacrificed and organs were collected at 
various DPI. Representative images are shown here. (A) The foot tissue appears 
normal but the C15Rev infected animals had increased virus within the tissue. (B) 
The popliteal LN has severe inflammation and necrosis in the C15Rev infected 
animals, but not C15stop, and increased virus throughout the LN of C15Rev infected 
animals. In the (C) inguinal LN 6 DPI there was little inflammation or necrosis of the 
LN, but increased viral staining in the C15Rev infected animals. (D) The spleen 
appears inflamed in all infected animals, however, the viral replication foci are larger 




which cross-reacts with ECTV. The sections in Fig. 4.6 show popliteal lymph nodes 
and the infected foot on day 4 and inguinal lymph node and spleen on day 6. At each 
time the infection by C15Rev was more advanced than that of C15Stop consistent 
with the data on virus loads. 
 
4.3.5 Cytokine levels in blood following infection 
The type of immunological response mounted against ECTV infection can have a 
strong impact on the likelihood of survival.  NK cells and CTLs have been implicated 
as essential for survival along with a strong and early production of IFN-γ, IL-2 
(315), IL-12 (316) and TNF-α (315); all components of a type 1 immune response. 
Characteristics of a type 2 immune response such as IL-4 (317), IL-5, IL-6 (214), and 
IL-13 (317) are more commonly observed in mice that succumb to mousepox 
infection. Granulocyte colony-stimulating factor (G-CSF) is important for neutrophil 
production (318) and increased in susceptible CAST/EiJ mice following MPXV 
infection, as were IL-6, CXCL1 (KC) and CXCL10 (IP-10) (319). 
The levels of 25 cytokines and chemokines in plasma from BALB/c were 
compared after footpad infection with 1,000 PFU of C15Stop or C15Rev. For most of 
the cytokines the levels were similar in mice infected with the two viruses. Equal or 
higher amounts of IFN-γ, IL-12p40, IL-6, G-CSF, CXCL1 and CXCL10 were 
detected in the plasma of C15Rev infected mice, however, only the increase in 
CXCL10 had high statistical significance (Fig. 4.7). Higher amounts of IL-2 and IL-5 
were found in C15Stop infected animals, but only the increase in IL-5 was 





Figure 4.7 Changes in blood cytokines in the absence of C15 
Plasma from 1,000 PFU footpad infected animals from Fig. 5 was used to examine 
blood cytokine levels for a panel of 25 cytokines. CXCL10 was present at 
significantly lower levels at day 6 following C15Stop infection (Mann-Whitney p < 
0.01). IL-5 was significantly increased in C15Stop infected animals (Mann-Whitney p 
< 0.05). Other key cytokines of the immune response were generally at equivalent or 
reduced levels  in the absence of C15, including IFN-γ, GCS-F, CXCL1, IL-4 and  





greater virus loads in mice infected with C15Rev than C15Stop. 
4.3.6 T cells are required for survival of mice following infection with C15Stop 
There are two general possibilities to account for the attenuation of C15Stop virus.  
One is that C15 directly enhances dissemination of ECTV and the other is that C15 
inhibits the host response to ECTV. If the former were true, then C15Stop might still 
be attenuated even if CD4+ or CD8+ T cells were depleted. Depletion was achieved 
with CD4- and CD8-specific mouse MAbs administered by intraperitoneal injection 
several days prior to infection. A non-targeting antibody of the same isotype was used 
as a control. At the time of infection, the extent of depletion of CD4 and CD8 cells  
was demonstrated in an independent experiment to be over 99% (data not shown). 
The footpads of 5 mice were inoculated with 1,000 PFU of C15Rev or C15Stop virus 
in each of two separate experiments. 70% of mice that received the control MAb 
succumbed to C15Rev, but only one animal infected with C15Stop died very late 
after infection on day 23 (Fig 4.8). In contrast, depletion of either or both CD4+ and 
CD8+ T cells accelerated the death of both C15Stop and C15Rev virus (Fig. 4.8). 
Thus, the decreased virulence of C15Stop was dependent on a functioning immune 
system.   
 
4.3.7 Mortality following intranasal infection 
To examine if the absence of C15 influences pathogenicity following different routes 
of infection we infected BALB/c mice intranasally with C15Rev or C15Stop (Figure 
4.9). Ten animals were observed over two independent experiments for changes in 




per animal we observed very little difference with 70% and 80% mortality in 
C15Stop and C15Rev, respectively. At lower doses there was distinctly less mortality 
following infection with C15Stop having 20% mortality at both doses, and C15Rev 
causing 60% and 80% mortality at 1 and 10 PFU, respectively. At 10 PFU this 
difference was significant (Mantle-Cox p = 0.2222). The LD50 of C15Rev was 
determined to be less than 1 PFU, for C15Stop it was 15.8 PFU. These results suggest 
that C15 influences pathogenesis in multiple routes of infection, reducing the lethality 
at low doses following intranasal infection, similar to the results seen following 
footpad infection. The recovery observed at very high doses following footpad 
infection was not observed following intranasal infection. 
 
4.3.8 Intracellular cytokine staining of IFN-γ in splenocytes 
In an attempt to evaluate the overall population of T cells and IFN-γ producing NK 
cells spleens of infected animals were collected at 3, 5, and 7 DPI. Spleens were 
homogenized and the red blood cells were digested away. A population of cells were 
labeled by antibodies against cell-type identifying surface receptors CD3 
(lymphocytes), CD19 (B cells), CD4 (T cells), CD8 (T cells), and CD49 (NK cells). 
Figure 4.10A shows the total number of viable cells from each condition. Note the 
inflammation as represented by an increase in cell number as compared to mock at 
day 3. By 7 DPI the C15Rev infected spleens are particularly unhealthy and have 
reduced numbers of viable cells. 
 In Figures 4.10B, C, and E the percentage of CD8+ T cells, NK cells and 




throughout the duration of the experiment. NK cells peak at approximately 10% at 5 
DPI and are roughly equivalent following infection with both viruses. On 3 and 7 DPI 
there is roughly 6% NK cells in the C15Stop infected spleens, and only 4% in the 
C15Rev infected. Like the CD8+ T cell levels, CD4+ T cells remain around 60% of 
CD3+ cells throughout the experiment. 
 Another population of splenocytes isolated were stimulated through direct 
infection with C15Stop virus. The C15Stop virus was used in the stimulation of all 
conditions to prevent the action of the C15 protein from preventing the activation of 
immune cells. Following overnight stimulation cells were again labeled for cell 
surface receptors and following fixation and permeabalization, for IFN-γ. In Figure 
4.10D the levels of IFN-γ of NK cells is shown with the peak also occurring 5 DPI.In 
the C15Stop infected animals a little over 1.5% of NK cells were stimulated to 
produce IFN-γ, but in the C15Rev this was only about 1%. In Figure 4.10F we see a 
less pronounced effect on IFN-γ of CD8+ T cells. Although there is a difference of 
roughly 0.3% and 0.15% between C15Stop and C15Rev, respectively, these are 
barely over the background of 0.1% IFN-γ producing cells from mock infected 
animals. Detection increases to about 0.6% by 7 DPI but there is less difference 
between viruses. 
 Together these data do not demonstrate a large change in the population of 
immune cell subsets of infected spleens, or the ability of these immune cells to be 








Figure 4.8 Effects of depletion of CD4+ and/or CD8+ T cells on survival 
Female 8-week old mice were injected in the intraperitoneal cavity with isotype 
control antibody, anti-CD4, and/or anti-CD8 antibody at three and five days prior to 
infection. Infections were performed by injecting the left hind footpad with 10 µl of 
1,000 PFU of C15Rev or C15Stop virus. Endpoints were determined by natural death, 
or in a few cases by determination of moribund status, followed by euthanasia. 






Figure 4.9 Mortality following intranasal infection 
Ten BALB/c mice were infected intranasally and observed across two independent 
experiments. Infectious doses ranged from 1 to 100 PFU per mouse. At the highest 
dose of 100 PFU, animals succumb to mousepox in equal numbers and at the same 
time. However, at lower doses of 1 and 10 PFU there was less observed mortality in 
the absence of C15. This difference was significant at 10 PFU (Mantel-Cox p = 
0.2222). The LD50 of C15Rev was less than 1 PFU per animal, and for C15Stop was 





Figure 4.10 Minimal changes in IFN-γ staining of cells isolated from the spleens of 
infected mice. 
Animals were infected via the footpad with 1,000 PFU of either C15Rev or C15Stop 
virus. Mock infected animals received only PBS+0.05% BSA. Animals were 
sacrificed 3, 5, and 7 DPI as labeled in parenthesis and spleens were harvested in 
RPMI on ice. Homogenates were treated to digest red blood cells and labeled with 




labeling for intracellular IFN- γ. In (A), the total number of viable cells per spleen are 
shown. The percent of viable cells decreases 7 DPI, especially in the C15Rev infected 
animals. In (B), (C), and (E) the percent of viable cells that are CD8+ T cells, CD49+ 
NK cells, and CD4+ T cells, respectively, are shown. There is no detectable levels of 
IFN-γ in CD8+ T cells following stimulation via C15Stop infection. In (D), the levels 
of IFN-γ staining of NK cells is shown. At 5 DPI the highest levels of IFN-γ are 
observed, and about 50% higher in the C15Stop animals. In (F) the IFN-γ staining 
levels of CD4+ T cells are shown. These levels increase through 7 DPI. There is 
approximately 50% more IFN-γ staining at 5 DPI, but at only very low levels. At 7 




The replicative ability of VACV, which lacks a B22 homolog, as well as CPXV (314) 
and MPXV (309) mutants had suggested that the protein is not required for an 
intrinsic viral function and likely has a role in host defense. However, the presence of 
B22 proteins in most poxviruses would mean that the host function has been 
conserved in fish, reptiles, birds and mammals. Nevertheless, deletion of the CPXV 
homolog did not attenuate pathogenicity in a mouse model (314). The latter 
hypothesis fit with the finding that the B22 proteins exhibits species specificity for 
inhibition of T cell activation and more specifically that the CPXV homolog does not 




whether the absence of the B22 homolog would attenuate pathogenicity of a poxvirus  
in a natural host e.g. footpad infection of mice by ECTV (121).  
 As expected from previous studies with CPXV and MPXV, the absence of 
C15 expression did not affect the replication of ECTV in cultured mouse cells and the 
particle to PFU ratios of control and mutant viruses were similar. However, greater 
mortality occurred at all doses tested when control virus was injected in the footpads 
of BALB/c mice compared to the C15 mutant. However, to our surprise mortality did 
not correlate with dose of the C15 mutant; at 1,000 PFU or more there was no 
mortality whereas approximately 50% of the mice died at doses of 10 to 100 PFU. To 
follow the course of infection, we determined the virus loads over time in the feet, 
popliteal and inguinal lymph nodes, liver and spleen. At the 1,000 PFU dose, in 
which all C15Rev mice died and all C15Stop mice survived, the titers of both viruses 
increased to the same extent in the foot indicating similar replication at the site of 
infection. However, there was significantly less C15Stop virus in the lymph nodes 
and internal organs compared to C15Rev accounting for the reduced mortality.  For 
C15Rev the virus titers in the foot and organs generally increased with virus dose. 
The virus titers also increased with dose in the foot following infection with C15Stop; 
however, the titers generally decreased with dose in the organs. Taking the data on 
mortality and virus titers together, the attenuation of C15Stop appears to be due to 
decreased spread from the foot to the lymph nodes and beyond.    
 Since the B22 homologs localize to the plasma membrane, it seemed possible 
that one role of the protein is to enhance virus spread directly. Alternatively, the 




inhibition of T cell activation in the MPXV model (309). If the role of the C15 
protein is to prevent T cell activation, then one might expect the virulence of C15Rev 
and C15Stop to be similar if T cells were depleted. On the other hand, if the role of 
C15 is to enhance virus spread directly, then there might still be a difference in 
virulence after T cell depletion. We found that the mortality increased to 100% when 
either CD4+ or CD8+ T cells were depleted, indicating that T cells provide important 
protection against C15Stop. Although it remains to be directly demonstrated, a 
greater T cell response could explain the reduced spread and mortality of C15Stop 
compared to C15Rev. Along the same lines, the innate immune response might 
develop more rapidly with higher doses of C15Stop thereby reducing spread from the 
foot to the lymph nodes or preventing virus replication there leading to the 
paradoxical effect of virus dose and survival. 
 The present study highlights the importance of matching virus with a natural 
host when studying the potential role of a viral immune modulator. Nevertheless, 
further studies are needed to determine why the B22 homolog enhances virulence of 
ECTV but not CPXV. The most interesting possibility is that the ECTV homolog is 
better adapted to interact with the mouse immune system, even though they are 92% 
identical in amino acid sequence. Alternatively, the difference may be due to viral 
genome backgrounds e.g. CPXV has many more host defense genes and there may be 
redundancy. Still a third possibility is the route of infection, which was intranasal in 





4.5 Materials and Methods 
4.5.1 Cells 
BS-C-1 cells were maintained at 37°C and 5% CO2 in modified Eagle minimal 
essential medium (EMEM, Quality Biologicals, Inc., Gaithersburg, MD) 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 10 U of 
penicillin/ml, and 10 mg of streptomycin/ml. HeLa and L929 cells were propagated in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and 
antibiotics as described above.  
4.5.2 Ectromelia virus 
Ectromelia virus Moscow Strain was obtained from ATCC (VR-1374) and passaged.  
A clonal isolate was derived and shown to replicate equivalently to the uncloned 
parental virus in tissue culture, and to have similar pathogenicity via footpad infection 
(data not shown). Purified virus was prepared as previously described (320). Briefly, 
BS-C-1 cells were infected with 1 PFU/cell for 48 to 72 h and cells were obtained by 
centrifugation, Dounce homogenized, and purified through a 36% sucrose cushion. 
The pellet was suspended in 1 mM Tris-HCl for use in animal experiments. All 
viruses were tested for bacterial contamination by removing a small volume, 
inoculating in LB broth at 37°C with shaking, and observing for turbidity. All virus 
preparations were negative. 
4.5.3 Generation of Recombinant Viruses 
Recombinant viruses were constructed from the ECTV-Mos clonal isolate. DNA 
sequences used for homologous recombination were generated by overlapping PCR 




amplified and used to flank the GFP open reading frame regulated by a VACV 
promoter, the unmodified C15 sequenve or a modified sequence containing two 
premature stop codons. To mutate the stop sequences the following primers were 
used with changes shown in bold: SR169.C15-R Stop 5'- GTA AGC TAT ATA GCC 
AGA GAT TAT TTC TGT AAA TTC ATG ATT G -3' and SR170.C15-F Stop 5'- 
CAA TCA TGA ATT TAC AGA AAT AAT CTC TGG CTA TAT AGC TTA C -3'. 
The ECTV-C15GFP was created by transfecting C15GFP DNA with Lipofectamine 
2000 (Invitrogen) into HeLa cells followed after 1 h by infection with ECTV-Mos. 
After 5 – 7 days incubation under 5% MethylCellulose-EMEM, virus was isolated 
from fluorescent plaques and then re-plaqued to clonal homogeneity. A similar 
procedure was used to derive C15Rev and C15Stop except that the ECTV-C15GFP 
was used as the parental virus and virus was obtained from non-fluorescent plaques. 
The recombinant DNA sequences for each virus were verified by PCR and 
sequencing. Viruses were propagated in BS-C-1 cells and released through three 
repeated freeze/thaw cycles. Samples were sonicated prior to each use and virus titers 
were determined in duplicate using BS-C-1 cells. 
4.5.4 Kinetics of virus growth in tissue culture. 
Mouse L929 cells were infected in triplicate at with 3 PFU/cell at 37°C in EMEM for 
1 h, washed three times with fresh, warm EMEM to remove the inoculum, and 
incubated at 37°C. Cells and media were harvested at appropriate times post-
infection, frozen and thawed three times and sonicated prior to titration on BS-C-1 
cells. The cell monolayers were overlaid with 5% Methylcellulose-EMEM for 6 days 





All experimental procedures involving mice were approved by the National Institutes 
of Allergy and Infectious Disease Animal Care and Use Committee and carried out in 
a humane manner. Female BALB/c mice were obtained from Taconic Biotechnology 
(Germantown, NY). Mice were maintained in a clean environment in small, static 
filter-top microisolator cages within an isolated room of an animal biosafety level 3 
suite in accordance with protocols approved by NIAID Animal Care and Use 
committee.    
 The virus inoculum was sonicated and diluted in phosphate buffered saline + 
0.05% bovine serum albumin and titered by plaque assay after each infection to 
confirm dosage. Groups of 5 female BALB/c mice 6 to 8 weeks old were sedated 
with isoflurane. A 25-27 gauge needle attached to a 25 µl gastight syringe (Hamilton) 
was inserted into the right hind footpad in the middle of the walking pads 8 to 10 mm 
beneath the skin. Mice were monitored daily and euthanized if they were determined 
to be moribund in accordance with NIAID Animal Care and Use protocols. 
4.5.6 Evaluation of disease and virus spread 
To monitor the progression of disease, animals were observed daily and given a score 
ranging from 0 (healthy) to 3 (severely ill) for each of the following categories: coat 
condition, movement/activity, eye condition, and limb swelling/necrosis. 
Veterinarians independently observed animals and made the determinations when one 
was moribund accordance to NIAID Animal Care and Use protocols. Foot 
measurements were performed using digital calipers to measure the thickest part of 




multiplying these measurements.  
 Blood was collected from the mandibular vein in polypropylene tubes with 
EDTA and processed by centrifugation at 2,000 x g for 8 min to pellet cells; the 
plasma was aliquoted and stored at -80oC. Animals were necropsied immediately 
after sacrifice and vital organs were collected including the inguinal and popliteal 
lymph node on the right side, the right hind foot, spleen and all lobes of the liver. 
Organs were placed in 1 to 2 ml of balanced salt solution containing 0.1% bovine 
serum albumin and stored at −80°C until use. Lymph nodes were Dounce 
homogenized and, other organs were homogenized with a GLH-1 mechanical grinder 
equipped with hard-tissue disposable probes and aerosol-proof caps (Omni 
International, Kennesaw, GA). After sonication, the homogenates were centrifuged 
for 10 s at 400 × g to remove cellular debris. Supernatants were aliquoted into fresh 
tubes and either frozen or used for virus titration by plaque assay on BS-C-1 cells. 
 Viral DNA was extracted through the use of the QIAamp MinElute Virus Spin 
Kit (Qiagen) according to the manufacturer’s protocol and stored at -20 °C. Genome 
copy number was determined through droplet digital PCR (BioRad) according to the 
manufacturer’s instructions. . Briefly, viral extracts from the MinElute spin kit were 
placed in a PCR plate with Evagreen supermix and primers targeting the E11 protein. 
Primer sequences were as follows: PXV(E11L)#2Rev_JA 5’ – GGT TCG TCA AAG 
ACA TAA AAC TCA TT -3’ and PXV(E11L)#3For_JA 5’ – GAA TAC ATT CAC 
ATT GAC CAA TCA GAA – 3’  Droplets were created in the automatic droplet 
generator, and genomes were amplified by PCR. Droplets were read in the BioRad 





4.5.7 Intranasal infection of animals. 
For intranasal inoculation, groups of 5 BALB/c mice were anesthetized with 
isofluorane and inoculated slowly in a single nostril with a 20 µl suspension of 
sucrose-cushion purified virus. Animals were tilted backwards for 30 sec before lying 
on their back to wake up to improve infection efficiency. Mice were weighed daily 
following infection and euthanized if they reached 70% of their initial body weight in 
accordance with NIAID Animal Care and Use protocols. The infection inoculum was 
sonicated prior to each use, and titered by plaque assay to confirm dosages after each 
infection. 
 
4.5.8 Quantitation of cytokines and chemokines in plasma of mice infected with 
ECTV 
Quantitation of 25 cytokines and chemokines (G-CSF, GM-CSF, IFN-γ, IL-1α, IL-1β, 
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-
17 IP-10 (CXCL10), KC (CXCL1), MCP-1, MIP-1α, MIP-1β, MIP-2, RANTES 
(CCL5), and TNF-α) in the plasma of BALB/c was performed with a Milliplex MAP 
Mouse Cytokine/Chemokine immunoassay kit (Millipore Corp., Billerica, MA) using 
a BioPlex 200 Luminex (Bio-Rad, Hercules, CA) according to the manufacturer’s 
instructions.  
4.5.9 T cell depletion 
MAbs against CD4 (clone GK1.5), CD8 (clone YTS 169.4), or KLH (isotype control, 
clone LTF-2)(Bio X Cell, Lebanon, NH) were utilized for T cell depletion.  Mice 




on days 3 and 4 before virus challenge. The efficacy of depletion was tested by flow 
cytometry of cells harvested from whole blood on days 5 and 13 and spleen when 






Chapter 5: Discussion and Future Directions 
 
 
5.1 Characterization of CPX219 
Our interest in the CPX219 protein emerged primarily from the uniqueness of its 
large size and the high level of conservation among chordopoxviruses for a protein in 
the variable region of the genome. The size of CPX219 posed unique challenges in 
the generation of recombinant viruses by homologous recombination and gel 
electrophoresis. Because early poxviral genes are transcribed from within the capsid, 
expression from a plasmid would require that expression be driven by a non-poxviral 
promoter, and so the ability to study the protein produced by the virus, not a plasmid, 
and was especially important for CPX219 which is regulated by an early promoter. 
Some early studies expressing CPX219 from a plasmid under a vaccinia early/late 
promoter led to significant over expression, accumulation in the ER, and thus 
improper glycosylation. This suggested to us expression from the viral genome was 
essential for future studies. Initial work was done using a mutant virus with only a C-
terminal epitope tag. It wasn’t until the addition of an N-terminal tag that a more 
complete picture of the biogenesis of CPX219 began to emerge. 
 The discovery of separate N- and C-terminal fragments was especially 
interesting and led to the use of BFA to confirm that this cleavage occurred 
intracellularly and not as an artifact ex vivo. These data also confirmed transport out 




glycosylation found on both fragments. As the cleave site(s) remain unknown, it is 
not possible to say if the two labeled fragments are the only fragments produced, or if 
additional internal fragments may exist due to multiple cleavage events. Indeed, on 
some western blots the C-terminal HA-tag is observed in multiple smaller bands. 
However, the sizes of deglycosylated fragments suggest that these two labeled 
fragments together are roughly the size of the full-length protein and would thus be 
the major fragments. Alzhanova et al (309) suggested that internal start sites could be 
responsible for the production of smaller fragments of CPX219. To test this we 
created a mutant in the first ATG allowing for the visualization of downstream, in 
frame, start site products but observed none. 
 
Another important attribute of CPX219 is the transmembrane domains that anchor it 
in the plasma membrane. Software prediction strongly suggested a C-terminal 
transmembrane domain, as well as at least 3 additional possible domains towards the 
center of the protein. Which of these transmembrane domains are used, and how 
many are real, remains unknown. However, access to the protein extracellularly by 
antibody to epitope tags, and the glycosylation of fragments suggests at least 1 
domain is responsible for looping the N-terminus and the majority of the protein to 
the extracellular space at the plasma membrane. 
 
CPX219 was not essential for viral replication in tissue culture, which along with its 
location in the variable region of the genome suggested a role in host interactions. To 




during intranasal infection of BALB/c mice and saw no difference in the absence of 
CPX219. This was also true in the CAST/EiJ mouse model, which has been shown in 
our lab to be highly susceptible to poxvirus infections (319). 
 
5.2 Mousepox disease and ectromelia C15 
Following our discovery that CPX219 did not influence pathogenicity in a mouse 
model, Alzhanova et al (309) demonstrated the ability of B22 homologs to reduce the 
activation state of both CD4+ and CD8+ T cells as measured by cytokine production. 
Interestingly, CPX219 was unable to enact this function on murine T cells. As 
Alzhanova et al. (309) examined the role of the MPXV B22 homolog, we next sought 
to examine the role of the B22 homolog in ECTV, C15. 
 
As with the generation of CPX219 recombinant, the large size of C15 posed 
difficulties in the creation of mutant viruses. This was also complicated by the slower 
growth of ECTV. For example, VACV can form plaques visible by the naked eye 
within 24 hr, for CPXV this is about 36 – 48 hr, but for ECTV it can take 4-5 days. In 
part for this reason, biogenesis studies confirming an expression pattern similar to 
CPX219 were not performed. A mutant was created that, like the CPX219 mutant, 
had premature stop codons resulting in the lack of protein production despite 
maintaining the presence of the coding sequences in the genome.  
 




C15Rev and C15Stop viruses, but unexpectedly we also observed reduced mortality 
at the highest doses with C15Stop. Stocks were tested to demonstrate the absence of 
bacterial contamination by incubation at 37 °C in LB with shaking, and the 
particle:PFU ratio was determined because  infectious dosages were calculated solely 
by PFU. This ratio was equivalent whether determined by staining for DNA and 
protein positive particles via the ViroCyt, or by measuring the genome copy number 
of particles by droplet digital PCR following benzonase digest to remove nucleic acid 
material outside of particles. In addition, using analysis of genome copy number in 
the absence of benzonase as a measurement for the purity of preparation we observed 
variation between different viral stock preparations, but not between viruses prepared 
at the same time. By these measurements the virus and innocula given during 
infection was equivalent, and does not explain the differences in mortality. 
 
Collection of organs at various DPI and following infection with different dosages 
provided some insight into the differences in mousepox disease progression in the 
absence of C15. Viral load at the site of infection (foot) was equivalent suggesting 
that changes in mortality were not due to reduced viral replication. In the lymph 
nodes viral load was reduced in the absence of C15, as well as in the critical spleen 
and liver. Significantly less virus in the liver in the absence of C15 may be the reason 
these animals can recover from the infection. Similarly, the higher mortality at lower 
doses of C15Stop may be due to higher viral loads in these key organs. These data 
were supported by histological analysis showing viral replication in key organs and 




changes remains unknown. 
 
Ectromelia virus spread has previously been demonstrated to be reduced in mouse 
strains inherently resistant to mousepox. One reason for this is the successful control 
of the infection and the generation of a strong and early type I response. To examine 
the immune response in the presence or absence of C15 we examined the cytokine 
levels in the blood. Although there are overall slightly higher cytokine levels in the 
blood in the presence of C15, we saw no shift in the cytokine profile to suggest that 
the immune response in the absence of C15 could explain the control of viral 
replication.  
 
We also evaluated the intranasal model of infection to determine if this was a route-
specific phenomenon. Although the mortality was less consistent than the footpad 
model of infection between experiments, we did observe reduced mortality in the 
absence of C15. However, unlike the footpad model, following intranasal infection 
mortality was reduced at lower doses. At higher doses the animals succumb to the 
disease at levels roughly equivalent to wildtype.  
 
5.3 Future Directions 
Much work remains before we will fully understand the role of B22 homologs during 
disease. Although Alzhanova et al (309) were able to determine that the MPXV 




remains unknown. T cells produce inhibitory signals, which could be engaged by the 
cell surface B22 homologs, although few direct viral-T cell inhibitory mechanisms 
have been described to date. In addition, the mousepox model provides a strong 
phenotype for the study of this homolog during disease and characterization of the 
mechanism of action, however the role of B22 needs to be confirmed at more 
physiologically relevant dosages.  
 
The role of CPX219 during CPXV infection could be masked by the redundancy of 
other immunomodulatory proteins. Specifically, CPXV expresses two proteins 
capable of inhibiting the expression of MHC class I molecules, which stimulate the 
TCR on CD8+ T cells. One method to assess the influence of redundancy would be 
the generation of recombinant viruses where CPXV expresses the ECTV-C15 protein 
in place of CPX219, and vice versa. During these infections the viral environment 
would be swapped and redundant CPXV proteins would have the ability to inhibit the 
function of ECTV-C15 and in the mousepox model CPX219 would be able to act in 
an environment that could allow us to observe its potential role during disease. This is 
one possible explanation for the lack of phenotype observed during cowpox infection 
in the absence of CPX219. Another explanation is the possibility that these homologs 
have species-specific abilities, supported by the finding that CPX219 only poorly 
inhibits murine CD8+ T cell activation. This suggests that B22 homologs could 
directly affect the role of T cells during infection. 
 




sequences between ECTV and CPXV are 92% identical, leaving little room for 
adaptation to the host. It is possible that this similarity could provide guidance in the 
determination of critical regions for species-specificity, host-interaction or 
performance of protein function. Amino acid alignment of B22 homologs has shown 
that the N-terminal region of the protein is more variable between viruses, and the C-
terminal region is more conserved. 
 
It would be interesting to preform studies on C15 similar to those carried out with 
CPX219 to determine if the cleavage event is conserved, or specific to the CPX219 
protein. The topology of the protein and its localization at the plasma membrane may 
be essential for understanding the role of this protein and so it would be ideal to see 
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